

Application of the modified Pictet-Spengler cyclization reaction for the preparation of imidazopyrazine ring: Synthesis of new pyrido- and pyrimido-imidazopyrazines

Sunil Sharma and Bijoy Kundu*

Medicinal and Process Chemistry Division, Central Drug Research Institute, Lucknow 226001, India

E-mail: bijoy_kundu@yahoo.com Tel.:+91 522 2612411-18x4383; fax:+91 522 2623405.

Abstract: An efficient and versatile method for the synthesis of imidazopyrazine ring using the modified Pictet-Spengler strategy has been reported. The two step strategy offers rapid assembly of drug-like core templates pyridine or pyrimidine and imidazole into new annulated polycyclic skeletons: pyrido- and pyrimido-imidazopyrazines. The rate of *endo* cyclization of aryl/heteroaryl- amine substrates have been compared with traditionally used aliphatic amine substrates and results have been discussed in the light of the pK_a values of amines present in each substrate.

Key words: Pictet Spengler reaction, cyclization, privileged structures, *N*-rich polycycles, fused-ring systems.

Introduction

In recent years there has been growing interest in using privileged heterocyclic structures¹ as starting point for library design.² The application of the privileged structure concept in the design of libraries can play a crucial role for the identification of high-affinity ligands.³ Out of several approaches applied for their generation, one way to design a library based on privileged structures is to construct new fused polycyclic structures. Almost unlimited combinations of annulated heterocyclic structures can be designed, resulting in novel polycyclic skeletons with the most diverse physical, chemical, and biological properties. In the literature compounds based on these templates have been reported to be associated with wide range of biological activities⁴ owing to their rigid conformation analogous to natural products. Therefore, development of an efficient method for the construction of fused polyheterocyclic ring systems in few steps is highly desirable, particularly in the field of medicinal chemistry.

A few years ago, we began to investigate the application of a modified Pictet-Spengler strategy⁵ involving aryl amine based substrate for the synthesis of fused *N*-polycyclic frameworks. The methodology involved condensation of carbonyls to aryl amine substrates linked to an activated heterocycle which proceeds through the intramolecular attack of a π nucleophilic carbon from the activated heterocycle onto the carbon of the iminium ion (π -cyclization). The efficacy of the strategy was successfully demonstrated by synthesizing both naturally occurring and privileged template-based polycyclic structures of biological interest either via 6- or 7-*endo* cyclization.

Though we successfully demonstrated the efficacy of our modified strategy on a host of activated and deactivated heterocyclic rings, the aryl amine component (in the form of tethered aniline) remained same in all the substrates. This prompted us to explore the affect of replacing the aryl amine with heteroaryl amine derived from either pyridine or pyrimidine rings as this would expand the repertoire of

our substrates amenable to the modified Pictet-Spengler reaction. Interestingly, both pyridine and pyrimidines belong to a class of heterocycles with proven utility (Privileged structure) in drug discovery therefore our strategy may offer scope for the engineering of biheterocycle frameworks into “privileged hybrid polycyclic skeletons”.

In order to explore the affect of heteroaryl amine on 6- *endo* cyclization, we proposed to replace the *N*-linked aryl amine moiety in one of our earliest reported imidazole-based substrate **1**^{5a} with 2-amino pyridine and 5-aminopyrimidine moieties thereby furnishing new substrates **2** and **3** (Figure 1).




Figure 1. Aryl/heteroaryl amine-based substrates for the modified Pictet-Spengler strategy.


Since **1** after condensation with aldehydes furnished imidazoquinoxalines^{5a} via the formation of imidazopyrazine ring, we envisaged that application of our modified Pictet-Spengler strategy to substrates **2** and **3** (with heteroaryl amines) would offer a general route to the synthesis of structurally diverse imidazopyrazine derivatives hitherto not reported.

In recent years imidazo[1,5-*a*]pyrazine scaffold has drawn significant interest among organic, medicinal and material scientists. The biheterocyclic system while on the one hand has been found to be ligands for the corticotropin releasing hormone receptor and for the human somatostatin receptor⁶ subtype 5, on the other hand, studies have established its efficacy for the treatment of acute ischemic stroke, as antioxidants⁷ and as inhibitors of insulin-like growth-factor-I receptor (IGF-IR)⁸, gastric H⁺/K⁺-ATPase⁹, CDK¹⁰ and IgE synthesis.¹¹ Beside this, imidazo[1,2-*a*]pyrazine-3-ones, have been isolated from a broad array of luminous marine organisms jellyfish (*Aequorea victoria*), sea pansy (*Renilla reniformis*), and squid (*Watasenia scintillans*).¹²

In the literature, synthesis of imidazo[1,5-*a*]pyrazine has been predominantly carried out either by the closure of the imidazole ring from substituted pyrazines¹³ or by generating pyrazine ring on imidazole derivatives.¹⁴ Other reports involve sequential ring closure of imidazole and pyrazine rings respectively¹⁵ and a three component reaction involving 2-aminopyrimidine, aldehydes and isonitrile using a nonpolar solvent.¹⁶ In the present paper, we report an application of the modified Pictet-Spengler strategy to tethered biheterocyclic substrates **2** and **3** for the generation of new imidazopyrazine based polycyclic structures.

Result and discussion

The substrate 2-imidazol-1-yl-pyridin-3-ylamine **2**, required as a key intermediate for the Pictet-Spengler reaction, was synthesized in two steps as depicted in Scheme 1. The synthesis commenced with the formation of nitro intermediates **4** by treating 2-chloro-3-nitro-pyridine **5** with imidazole derivatives **6** in DMF at 110 °C. The resulting nitro derivatives **4a-c** was then treated with Fe in HCl/ethanol under reflux to give **2a-c** in excellent yields.



6a, 4a, 2a (R¹ = C₂H₅, R² = CH₃)

6b, 4b, 2b (R¹ = C₆H₅, R² = H)

6c, 4c, 2c (R¹ = C₆H₅, R² = CH₃)


Scheme 1. Reagents and conditions: (i) DMF, 110 °C, 36 h. (ii) Fe, HCl/C₂H₅OH, reflux, 1 h.

We next explored efficacy of **2** to undergo π -cyclizations with a variety of aldehydes and ketones. In the first instance, the substrate **2a** was subjected to the Pictet-Spengler reaction by treating it with 4-ethoxybenzaldehyde using several acidic protocols (Table 1). Best results were obtained when substrate **2a** was treated with 4-ethoxybenzaldehyde in 1% TFA in toluene at reflux. Initially, the product was obtained as a mixture of two components as evident by both HPLC and TLC. The two spots were then separated by column chromatography and characterized by ESMS and NMR. One of the major components with a lower R_f on TLC and with a mass of 335.3 Da was found to be dihydroimidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine and the second component with a higher R_f and a mass of 333.3 Da was identified as imidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine **7a**, an oxidized product of the first component. Of these two, dihydroimidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine had moderate stability, because even after purification, it

Table 1. Optimization of reaction conditions for the conversion of **2a** into **7a** via 6-*endo* cyclization

S. No.	2a + 4-ethoxybenzaldehyde + acidic protocols	Isolated yield 7a (%)
1	<i>p</i> -TsOH in toluene at reflux	35
2	10% AcOH in ethanol at reflux	26
3	5% TFA in CH ₂ Cl ₂ at r.t. and DDQ	32
4	Yb(OTf) ₃ in CH ₃ CN and DDQ	<20
5	1%TFA in toluene at reflux and DDQ	90

had a tendency to undergo slow oxidation to **7a**. We therefore, used DDQ as an oxidizing agent in the final step after the Pictet-Spengler cyclization that furnished annulated polycyclic compound imidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine **7a** as a single product. The annulation of the substrate **2a** occurred via C-C bond formation between the C-5 of the electron rich imidazole moiety and carbon of the imine (Scheme 2). Literature search revealed only one single report dealing with synthesis of compounds based on imidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine framework associated with antiinflammatory activity.¹⁷ The scope and limitation of this reaction was further studied by treating substrates **2a-c** with various



Scheme 2. Reagents and conditions: (i) R³CHO, 1% TFA in toluene, 120 °C. (ii) DDQ, 10 min

aliphatic and aromatic aldehydes and results have been summarized in table 2.

Substitution on substrates **2a-c** had no effect on the rate of *endo* cyclization and furnished cyclized products **7a-m** in excellent yields. Similarly, aldehydes with both electron-donating and withdrawing groups underwent 6-*endo* cyclization within 1-5 h, however, reaction with propionaldehyde went at slow pace (Table 2, entry 11).

Next, we examined the ability of substrate **2** to undergo *endo* cyclization with ketones (Scheme 3), which is traditionally known to be a sluggish reaction. Both aliphatic and aromatic ketones were subjected to the Pictet-Spengler reaction by treating substrates **2a-b** with ketones in the presence of 1% TFA in toluene and the results have been summarized in table 3. Both the substrates underwent 6-*endo*


Table 2. Synthesis of imidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine **7a-m**

Entry	Substrate	R ³	Product	Time (h)	Yield (%) ^a
1	2a	4-OC ₂ H ₅ -C ₆ H ₄	7a	1	90
2	2a	2-OH-C ₆ H ₄	7b	1	88
3	2a	4-OCH ₃ -C ₆ H ₄	7c	1	92
4	2a	4-Cl-C ₆ H ₄	7d	0.5	90
5	2a	4-NO ₂ -C ₆ H ₄	7e	0.5	92
6	2a	H	7f	1	91
7	2b	4-CH ₃ -C ₆ H ₄	7g	3	89
8	2b	4-(CH ₃) ₂ N-C ₆ H ₄	7h	5	83
9	2b	4-OCH ₃ -C ₆ H ₄	7i	5	82

10	2b	C ₆ H ₅	7j	4	88
11	2b	C ₂ H ₅	7k	8	80
12	2c	4-Br-C ₆ H ₄	7l	4	89
13	2c	4-NO ₂ -C ₆ H ₄	7m	2	90

^a Isolated yield

Cyclization to furnish **8a-h** in excellent yields; however, rate of cyclization was found to be comparatively less than that observed during condensation with aldehydes. Both the 6-*endo* cyclized products based on **7** and **8** are based on 6,6,5-fused tricyclic systems. Compounds based on 6, 6, 5-



Scheme 3. Reagents and condition: (i) R³COR⁴, 1% TFA in toluene, 120 °C.

Table 3. Synthesis of 5,6-dihydroimidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine **8a-h**

Entry	Substrate	R ³	R ⁴	Product	Time (h)	Yield (%) ^a
1	2a	CH ₃	C ₆ H ₅	8a	9	72
2	2a	CH ₃	C ₂ H ₅	8b	1.5	83
3	2a	CH ₃	CH ₃	8c	1	86
4	2a	R ³ and R ⁴ =C ₆ H ₁₀		8d	1.5	85
5	2a	R ³ and R ⁴ =C ₃ H ₈		8e	1	84
6	2b	CH ₃	CH ₃	8f	4	94
7	2b	CH ₃	C ₂ H ₅	8g	6	88
8	2b	R ³ and R ⁴ =C ₆ H ₁₀		8h	6	93

^a Isolated yield

systems are widely distributed in nature¹⁸ and have been reported to be useful drug leads for a variety of diseases.¹⁹

After successfully demonstrating the efficacy of our strategy on substrate **2**, we next examined the efficacy of the substrate **3** having *N*-linked pyrimidine amine towards *endo* cyclization. Synthesis of **3** was initially attempted by treating 4,6-dichloro-5-nitro pyrimidine **9** with the imidazole **6a**, however, the product was obtained as a mixture of both mono- and di-substituted pyrimidines. This led us to modify our strategy by selectively and sequentially replacing chloro group at position 4 in **9** with diethyl amine followed by nucleophilic replacement of chloro group at position 6 with the NH of imidazoles to furnish nitro derivatives **11a-b** (Scheme 4). Next, the nitro group in intermediate **11a-b** was reduced by treating with Fe/HCl to furnish the desired heteroarylamine substrates **3a-b**.

21	3b	CH ₃	C ₂ H ₅	13c	6	57
22	3b	CH ₃	C ₆ H ₅	13d	18	48

cyclization. This is in contrast to traditionally used aliphatic amine substrates (Tryptophan/tryptamine) that are either adamant or sluggish to *endo* cyclization when treated with aldehydes having electron-donating group (e.g salicylaldehyde and *p*-*N*, *N*-dimethyl benzaldehyde). Cook et al.²⁰ attributed electrophilicity of the imine double bond resulting from the condensation of amines and aldehydes as the limiting factor for the Pictet–Spengler cyclization and applied p*K*_a values of amines to compare the electrophilicities of the ‘imines’. They argued that amines with comparatively lower p*K*_a value such as Trp (7.2) exhibit high order of reactivity towards *endo* cyclization than tryptamine with relatively higher p*K*_a value (10.2). Accordingly, we compared the reactivities of Trp-OMe and tryptamine with substrates **1**, **2** and **3** towards *endo* cyclization when condensed with salicylaldehyde under similar reaction conditions and the results have been summarized in table 5. As expected aliphatic amine derived substrates Trp-OMe and tryptamine were indeed sluggish towards *endo* cyclization, however, aryl/heteroaryl amine-based substrates (**1**, **2a** and **3a**) underwent *endo* cyclization with relative ease and in high yields. This observation can be explained by comparing the p*K*_a values of the substrates (tryptamine 10.2, Trp-OMe 7.29, substrate **1** with the aniline 4.2, substrate **2** with 2-amino pyridine 6.82 **Table 5**. Comparative profile of the 6-*endo* cyclization of aliphatic/aryl amine-based substrates with salicylaldehyde using 1% TFA in toluene at 120 °C

Entry	Substrate	p <i>K</i> _a	Time (h)	Yield (%) ^b
1	Trp-OMe	7.2	24	45
2	Tryptamine	10.2	24	19
3	1 ^a	4.2	1	86
4	2a	6.8	1	88
5	3a	2.8	8	70

^a R¹= C₂H₅; R²= CH₃; ^b Isolated yield of 6-*endo* cyclized products

and substrate **3** with 5-amino pyrimidine 2.83) which clearly suggests that the carbon–nitrogen double bond in the imines derived from substrates **1-3** due to relatively higher electrophilicity than imines derived from Trp-OMe and tryptamine, undergo 6- *endo* cyclization with greater ease when condensed with salicylaldehyde.

It is worth mentioning that substrates **2** and **3** have the heteroaryl moiety in “meta” relative to the nitrogen atom present in the heteroarene ring. This could be a relevant factor for the first step of the reaction that is imine formation since the “meta” position of *N*-containing deactivate heterocyclic (such as pyridine and pyrimidine) remains the only one not affected by the strong resonance effect of *endo* cyclic pyridine-type nitrogen atom. As a consequence, an amino group “meta” could be much more nucleophilic than an amino group when present in “ortho or para” (where the lone pair of the amino groups is highly delocalized within the ring). Thus, the position of amino in substrate **2** and **3** may have contributed in facilitating π cyclization, however this needs to be investigation by incorporating other aminopyridine and aminopyrimidine isomers.²¹

Conclusion

We have developed an efficient and versatile method for the preparation of pyridino- and-pyrimidino-imidazopyrazine derivatives based on 6,6,5 tricyclic systems using the modified Pictet–Spengler reaction. Extension of π -cyclization reactions from aryl amine-based substrates to heteroaryl amine-based substrates opens up new avenues for the synthesis of annulated polycyclic heterosystems from tethered biheterocyclic substrates in minimal steps. Currently studies are in progress to extend the modified Pictet–Spengler strategy to the synthesis of natural product and their derivatives.

Experimental

All solvents were commercially available and used without purification. All products were characterized by ^1H NMR, ^{13}C NMR, ESMS, and IR. Analytical TLC was performed using 2.5 x 5 cm plated coated with a 0.25 mm thickness of silica gel. 60F-254 and visualization was accomplished with UV light and iodine. Column chromatography was performed using silica gel (100-200 mesh). ^1H NMR spectra (200/300 MHz) are reported as follows: chemical shifts in ppm downfield from TMS as internal standard (δ scale), multiplicity [br=broad, s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, o=overlapped, integration and coupling constant (Hz)]. All ^{13}C NMR spectra (50/75 MHz) were recorded at 25 °C with complete proton decoupling and reported in ppm except for compounds **7b**, **12f**, and **12k** which are insoluble at higher concentration. The purity and characterization of these compounds were further established using HR/EI Mass spectroscopy. Elemental analyses were performed on microanalyzer or Elementar's Vario EL III microanalyzer. The micro-analyses were performed at Sophisticated Analytical Instrument Facility Division, CDRI. Mass spectra were recorded on a spectrometer and EI Mass spectra were done on JEOL-600H at 70eV. Melting points reported were uncorrected.

General Procedure for the Synthesis of Nitro Derivative (4):

A mixture of 2-chloro-3-nitro-pyridine **5** (790 mg, 5 mmol) and imidazole **6a** (1.10 g, 10 mmol) in DMF (1 mL) in a vessel was heated at 110 °C for 36 h. Upon completion of the reaction, the reaction mixture was cooled to room temperature and diluted with ethyl acetate (100 mL). The solvent was washed with water (2 x 40 mL), brine (40 mL), and finally dried over anhydrous Na_2SO_4 . The organic layer was evaporated *in vacuo* to afford a crude residue which was purified by column chromatography on silica gel using hexane-ethyl acetate (35:65, v/v) to give the desired product **4a**.

2-(2-Ethyl-4-methyl-1H-imidazol-1-yl)-3-nitropyridine (4a):

Yield: 67%; yellow solid; mp 71-73 °C; $R_f = 0.69$ (1:9, MeOH/ CHCl_3); IR (KBr) ν_{max} 3019, 2975, 2851, 1594, 1536, 1351 cm^{-1} ; ^1H NMR (200 MHz, CDCl_3) $\delta = 8.80$ (dd, $J = 4.7, 1.7$ Hz, 1 H, ArH), 8.36 (dd, $J = 8.1, 1.7$ Hz, 2 H, ArH), 7.62-7.56 (m, 1 H, ArH), 6.65 (d, $J = 1.1$ Hz, 1 H, ArH), 2.66 (q, $J = 7.5$ Hz, 2 H, CH_2), 2.24 (d, $J = 1.1$ Hz, 3 H, CH_3), 1.23 (t, $J = 7.5$ Hz, 3 H, CH_3); mass (ES^+) m/z 233.3 [(M+1) $^+$]; Anal. Calcd for $\text{C}_{11}\text{H}_{12}\text{N}_4\text{O}_2$: C, 56.89; H, 5.21; N, 24.12. Found: C, 56.78; H, 5.28; N, 24.18.

3-Nitro-2-(2-phenyl-1H-imidazol-1-yl)pyridine (4b):

Yield: 52%; yellow solid; mp 112-114 °C; $R_f = 0.76$ (1:9, MeOH/ CHCl_3); IR (KBr) ν_{max} 3021, 2922, 2862, 1594, 1528, 1346 cm^{-1} ; ^1H NMR (200 MHz, CDCl_3) $\delta = 8.83$ (dd, $J = 4.7, 1.7$ Hz, 1 H, ArH), 8.24 (dd, $J = 8.1, 1.7$ Hz, 1 H, ArH), 7.62-7.56 (m, 1 H, ArH), 7.34-7.22 (m, 7 H, ArH); ^{13}C NMR (75 MHz, CDCl_3) $\delta = 162.6, 153.0, 147.8, 143.8, 141.8, 134.5, 130.2, 129.2, 128.7, 128.5, 124.7, 121.0$; mass (ES^+) m/z 267.1 [(M+1) $^+$]; Anal. Calcd for $\text{C}_{14}\text{H}_{10}\text{N}_4\text{O}_2$: C, 63.15; H, 3.79; N, 21.04. Found: C, 63.21; H, 3.64; N, 21.11.

2-(4-Methyl-2-phenyl-1H-imidazol-1-yl)-3-nitropyridine (4c):

Yield: 46%; yellow solid; $R_f = 0.78$ (1:9, MeOH/ CHCl_3); IR (KBr) ν_{max} 3020, 2983, 2849, 1578, 1378 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) $\delta = 8.79$ (dd, $J = 4.7, 1.5$ Hz, 1 H, ArH), 8.20 (dd, $J = 8.1, 1.5$ Hz, 1 H, ArH), 7.56-7.52 (m, 1 H, ArH), 7.28-7.22 (m, 5 H, ArH), 7.06 (s, 1 H, ArH), 2.37 (s, 3 H, CH_3); ^{13}C NMR (75 MHz, CDCl_3) $\delta = 152.8, 152.7, 152.5, 147.0, 139.4, 138.1, 134.3, 129.3, 129.0, 128.6, 128.4, 124.1, 13.5$; mass (ES^+) m/z 281.2 [(M+1) $^+$]; Anal. Calcd for $\text{C}_{15}\text{H}_{12}\text{N}_4\text{O}_2$: C, 64.28; H, 4.32; N, 19.99. Found: C, 64.37; H, 4.45; N, 19.87.

General Procedure for the Synthesis of Amine Derivative (2):

A solution of **4a** (1.16 g, 5 mmol) and Fe (1.10, 20 mmol) in acidic ethanol (1:4 HCl/EtOH), was refluxed under nitrogen atmosphere for 1 h. The reaction mixture was allowed to cool down and then poured into ice, the pH is made slightly basic (pH 8) by addition of 5% aqueous NaHCO_3 . The ethyl acetate (100 mL) was added to the mixture and filtered through a bed of celitet. The organic layer was finally washed with water (2 x 50 mL), brine (2 x 50 mL) and dried over anhydrous Na_2SO_4 . The organic layer was evaporated to dryness under reduced pressure. The crude product was purified on a silica gel column using hexane-ethyl acetate (20:80, v/v) as eluent to afford **2a**.

2-(2-Ethyl-4-methyl-1H-imidazol-1-yl)pyridin-3-amine (2a):

Yield: 90%; white solid; mp 162-165 °C; $R_f = 0.44$ (1:9, MeOH/CHCl₃); IR (KBr) ν_{\max} 3184, 3116, 2937, 2875, 1643 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) $\delta = 7.96$ -7.93 (m, 1 H, ArH), 7.22 (d, $J = 3.0$ Hz, 2 H, ArH), 6.79 (s, 1 H, ArH), 4.15 (brs, 2 H, NH₂), 2.73 (q, $J = 7.4$ Hz, 2 H, CH₂), 2.34 (s, 3 H, CH₃), 1.25 (t, $J = 7.4$ Hz, 3 H, CH₃); ¹³C NMR (75 MHz, CDCl₃) $\delta = 149.8$, 138.6, 138.5, 137.5, 136.7, 125.1, 123.9, 114.8, 20.6, 13.6, 12.3; mass (ES⁺) m/z 203.2 [(M+1)⁺]; Anal. Calcd for C₁₅H₁₄N₄: C, 65.32; H, 6.98; N, 27.70. Found: C, 65.48; H, 6.87; N, 27.65.

2-(2-Phenyl-1H-imidazol-1-yl)pyridin-3-amine (2b):

Yield: 74%; white solid; mp 147-150 °C; $R_f = 0.51$ (1:9, MeOH/CHCl₃); IR (KBr) ν_{\max} 3167, 3112, 3021, 1624 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) $\delta = 7.98$ (dd, $J = 4.5$, 1.4 Hz, 1 H, ArH), 7.47-7.43 (m, 2 H, ArH), 7.32-7.17 (m, 6 H, ArH), 7.08 (dd, $J = 8.0$, 1.4 Hz, 1 H, ArH), 3.59 (brs, 2 H, NH₂); ¹³C NMR (75 MHz, CDCl₃) $\delta = 146.9$, 138.7, 138.6, 137.1, 130.3, 129.9, 128.8, 128.5, 127.7, 125.6, 124.4, 121.4; mass (ES⁺) m/z 237.2 [(M+1)⁺]; Anal. Calcd for C₁₄H₁₂N₄: C, 71.17; H, 5.12; N, 23.71. Found: C, 71.28; H, 5.06; N, 23.66.

2-(4-Methyl-2-phenyl-1H-imidazol-1-yl)pyridin-3-amine (2c):

Yield: 68%; white solid; mp 145-147 °C; $R_f = 0.53$ (1:9, MeOH/CHCl₃); IR (KBr) ν_{\max} 3189, 3121, 3022, 2948, 2836, 1635 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) $\delta = 7.96$ (dd, $J = 4.5$, 1.6 Hz, 1 H, ArH), 7.45-7.40 (m, 2 H, ArH), 7.25-7.05 (m, 5 H, ArH), 6.89 (d, $J = 0.9$ Hz, 1 H, ArH), 3.62 (brs, 2 H, NH₂), 2.35 (d, $J = 0.8$ Hz, 3 H, CH₃); ¹³C NMR (75 MHz, CDCl₃) $\delta = 146.7$, 138.5, 138.4, 136.9, 130.1, 129.7, 128.5, 128.2, 127.4, 125.3, 124.1, 121.1; 13.1; mass (ES⁺) m/z 251.2 [(M+1)⁺]; Anal. Calcd for C₁₅H₁₄N₄: C, 71.98; H, 5.64; N, 22.38. Found: C, 71.89; H, 5.80; N, 22.31.

General Procedure for the Synthesis of Imidazo[1,5-a]pyrido[3,2-e]pyrazine (7):

A mixture of amine **2a** (202 mg, 1 mmol) and 4-ethoxybenzaldehyde (150 μ L, 1 mmol) was refluxed in 1% TFA in toluene until the disappearance of the starting material on TLC. Then, the reaction mixture was treated with DDQ (1.5 mmol) for 10 min at reflux. Toluene was evaporated in vacuo, and the residue so obtained was basified with aq. NaHCO₃ and extracted with ethyl acetate (2 x 30 mL). The organic layers were washed with brine (10 mL), and dried over anhydrous Na₂SO₄. The ethyl acetate was evaporated under reduced pressure to obtain residue that after column chromatography on silica gel using hexane-ethyl acetate (60:40 v/v) afforded **7a** as white solid.

6-(4-Ethoxyphenyl)-9-ethyl-7-methylimidazo[1,5-a]pyrido[3,2-e]pyrazine (7a):

Yield: 90%; white solid; mp 146-147 °C; $R_f = 0.64$ (2:3, EtOAc/Hexane); IR (KBr) ν_{\max} 3021, 2930, 2849, 1607 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) $\delta = 8.49$ (dd, $J = 4.5$, 1.4 Hz, 1 H, ArH), 8.19 (dd, $J = 7.9$, 1.4 Hz, 1 H, ArH), 7.57 (d, $J = 8.6$ Hz, 2 H, ArH), 7.45-7.41 (m, 1 H, ArH), 7.04 (d, $J = 8.6$ Hz, 2 H, ArH), 4.14 (q, $J = 7.0$ Hz, 2 H, CH₂), 3.71 (q, $J = 7.0$ Hz, 2 H, CH₂), 2.20 (s, 3 H, CH₃), 1.53-1.46 (m, 6 H, 2 x CH₃); ¹³C NMR (75 MHz, DMSO) $\delta = 149.6$, 146.9, 143.5, 136.2, 135.9, 132.7, 131.9, 129.5, 128.0, 127.1, 124.2, 123.9, 122.6, 122.5, 51.2, 12.3; mass (ES⁺) m/z 333.3 [(M+1)⁺]; Anal. Calcd for C₂₀H₂₀N₄O: C, 72.27; H, 6.06; N, 16.86. Found: C, 72.31; H, 6.11; N, 16.78.

2-(9-Ethyl-7-methylimidazo[1,5-a]pyrido[3,2-e]pyrazin-6-yl)phenol (7b):

Yield: 88%; white solid; mp > 250 °C; $R_f = 0.61$ (2:3, EtOAc/Hexane); IR (KBr) ν_{\max} 3021, 2978, 2855, 1603 cm⁻¹; ¹H NMR (300 MHz, DMSO) $\delta = 9.73$ (brs, 1 H, OH), 8.59 (dd, $J = 4.6$, 1.4 Hz, 1 H, ArH), 8.23 (dd, $J = 7.9$, 1.6 Hz, 1 H, ArH), 7.62-7.58 (m, 1 H, ArH), 7.39-7.34 (m, 1 H, ArH), 7.28 (dd, $J = 7.4$, 1.4 Hz, 1 H, ArH), 7.00-6.96 (m, 2 H, ArH), 3.57 (q, $J = 7.4$ Hz, 2 H, CH₂), 1.94 (s, 3 H, CH₃), 1.38 (t, $J = 7.4$ Hz, 3 H, CH₃); mass (ES⁺) m/z 305.3 [(M+1)⁺]; Anal. Calcd for C₁₈H₁₆N₄O: C, 71.04; H, 5.30; N, 18.41. Found: C, 71.14; H, 5.17; N, 18.32.

9-Ethyl-6-(4-methoxyphenyl)-7-methylimidazo[1,5-a]pyrido[3,2-e]pyrazine (7c):

Yield: 92%; yellow solid; mp 156-158 °C; $R_f = 0.35$ (3:7, EtOAc/Hexane); IR (KBr) ν_{\max} 3021, 2978, 2855, 1603 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) $\delta = 8.49$ (dd, $J = 4.6$, 1.7 Hz, 1 H, ArH), 8.18 (dd, $J = 7.9$, 1.7 Hz, 1 H, ArH), 7.58 (d, $J = 8.8$ Hz, 2 H, ArH), 7.45-7.39 (m, 1 H, ArH), 7.04 (d, $J = 8.8$ Hz, 2 H, ArH), 3.90 (s, 3 H, OCH₃), 3.69 (q, $J = 7.4$ Hz, 2 H, CH₂), 2.18 (s, 3 H, CH₃), 1.49 (t, $J = 7.4$ Hz, 3 H, CH₃); ¹³C NMR (50 MHz, CDCl₃) $\delta = 161.2$, 157.3, 148.2, 146.0, 140.1, 137.2, 136.6, 132.2, 130.4,

130.3, 122.7, 122.3, 114.0, 55.6, 24.7, 16.4, 12.6; mass (ES⁺) *m/z* 319.4 [(M+1)⁺]; Anal. Calcd for C₁₉H₁₈N₄O: C, 71.68; H, 5.70; N, 17.60. Found: C, 71.74; H, 5.62; N, 17.54.

6-(4-Chlorophenyl)-9-ethyl-7-methylimidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine (7d):

Yield: 90%; yellow solid; mp 193-195 °C; R_f = 0.53 (2:3, EtOAc/Hexane); IR (KBr) ν_{max} 3051, 2924, 2862, 1595 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ = 8.52 (dd, *J* = 4.7, 1.7 Hz, 1 H, ArH), 8.19 (dd, *J* = 8.0, 1.7 Hz, 1 H, ArH), 7.60-7.41 (m, 5 H, ArH), 3.70 (q, *J* = 7.4 Hz, 2 H, CH₂), 2.15 (s, 3 H, CH₃), 1.49 (t, *J* = 7.4 Hz, 3 H, CH₃); ¹³C NMR (50 MHz, CDCl₃) δ = 156.5, 148.6, 146.7, 140.2, 137.4, 137.0, 136.6, 136.4, 132.2, 130.4, 129.2, 122.7, 25.0, 16.5, 12.8; mass (ES⁺) *m/z* 323.3 [(M+1)⁺]; Anal. Calcd for C₁₈H₁₅ClN₄: C, 66.98; H, 4.68; N, 17.36. Found: C, 66.82; H, 4.75; N, 17.44.

9-Ethyl-7-methyl-6-(4-nitrophenyl)imidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine (7e):

Yield: 92%; yellow solid; mp 182-183 °C; R_f = 0.45 (2:3, EtOAc/Hexane); IR (KBr) ν_{max} 3080, 2923, 2858, 1594 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ = 8.56 (dd, *J* = 4.7, 1.7 Hz, 1 H, ArH), 8.41 (d, *J* = 8.8 Hz, 2 H, ArH), 8.21 (dd, *J* = 8.0, 1.7 Hz, 1 H, ArH), 7.82 (d, *J* = 8.8 Hz, 2 H, ArH), 7.51-7.45 (m, 1 H, ArH), 3.72 (q, *J* = 7.4 Hz, 2 H, CH₂), 2.13 (s, 3 H, CH₃), 1.50 (t, *J* = 7.4 Hz, 3 H, CH₃); ¹³C NMR (50 MHz, CDCl₃) δ = 169.1, 154.8, 148.6, 146.8, 143.7, 139.7, 136.8, 132.7, 131.5, 129.7, 128.1, 123.6, 122.4, 24.3, 15.9, 12.3; mass (ES⁺) *m/z* 334.3 [(M+1)⁺]; Anal. Calcd for C₁₈H₁₅N₅O₂: C, 64.86; H, 4.54; N, 21.01. Found: C, 64.77; H, 4.63; N, 21.11.

9-Ethyl-7-methylimidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine (7f):

Yield: 91%; white solid; mp 99-101 °C; R_f = 0.26 (2:3, EtOAc/Hexane); IR (KBr) ν_{max} 3058, 2925, 2855, 1617 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 8.71 (s, 1 H, ArH), 8.50 (dd, *J* = 4.7, 1.7 Hz, 1 H, ArH), 8.16 (dd, *J* = 7.9, 1.7 Hz, 1 H, ArH), 7.45-7.41 (m, 1 H, ArH), 3.65 (q, *J* = 7.5 Hz, 2 H, CH₂), 2.62 (s, 3 H, CH₃), 1.47 (t, *J* = 7.5 Hz, 3 H, CH₃); ¹³C NMR (50 MHz, CDCl₃) δ = 148.1, 146.6, 146.2, 137.0, 136.8, 132.2, 123.8, 122.3, 24.5, 13.0, 12.5; mass (ES⁺) *m/z* 213.3 [(M+1)⁺]; Anal. Calcd for C₁₂H₁₂N₄: C, 67.90; H, 5.70; N, 26.40. Found: C, 67.87; H, 5.64; N, 26.49.

9-Phenyl-6-*p*-tolylimidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine (7g):

Yield: 89%; white solid; mp 181-183 °C; R_f = 0.58 (3:7, EtOAc/Hexane); IR (KBr) ν_{max} 3021, 2918, 2844, 1606 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 8.31-8.28 (m, 2 H, ArH), 8.03-7.88 (m, 5 H, ArH), 7.51-7.39 (m, 6 H, ArH), 2.49 (s, 3 H, CH₃); ¹³C NMR (50 MHz, CDCl₃) δ = 155.7, 145.9, 141.4, 138.8, 137.5, 134.3, 132.4, 132.2, 130.7, 130.2, 129.8, 129.1, 128.6, 127.6, 127.0, 123.2, 21.7; mass (ES⁺) *m/z* 337.4 [(M+1)⁺]; Anal. Calcd for C₂₂H₁₆N₄: C, 78.55; H, 4.79; N, 16.66. Found: C, 78.65; H, 4.64; N, 16.71.

***N,N*-Dimethyl-4-(9-phenylimidazo[1,5-*a*]pyrido[3,2-*e*]pyrazin-6-yl)aniline (7h):**

Yield: 83%; orange solid; mp 168-170 °C; R_f = 0.54 (2:3, EtOAc/Hexane); IR (KBr) ν_{max} 3021, 2918, 2856, 1607 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 8.26-8.21 (m, 2 H, ArH), 8.07-8.02 (m, 3 H, ArH), 7.91-7.89 (m, 2 H, ArH), 7.49-7.39 (m, 4 H, ArH), 6.86 (d, *J* = 7.7 Hz, 2 H, ArH), 3.09 (s, 6 H, 2 x CH₃); ¹³C NMR (50 MHz, CDCl₃) δ = 155.2, 152.4, 145.5, 145.0, 138.7, 136.9, 132.7, 132.5, 130.7, 130.0, 129.2, 127.5, 127.0, 124.6, 123.0, 112.0, 109.7, 40.3; mass (ES⁺) *m/z* 366.4 [(M+1)⁺]; Anal. Calcd for C₂₃H₁₉N₅: C, 75.59; H, 5.24; N, 19.16. Found: C, 75.69; H, 5.19; N, 19.12.

6-(4-Methoxyphenyl)-9-phenylimidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine (7i):

Yield: 82%; white solid; mp 169-170 °C; R_f = 0.42 (3:7, EtOAc/Hexane); IR (KBr) ν_{max} 3046, 2924, 2854, 1607 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ = 8.30-8.27 (m, 1 H, ArH), 8.26 (s, 1 H, ArH), 8.07-8.03 (m, 3 H, ArH), 7.92-7.87 (m, 2 H, ArH), 7.51-7.41 (m, 4 H, ArH), 7.11 (d, *J* = 8.8 Hz, 2 H, ArH), 3.92 (s, 3 H, CH₃); ¹³C NMR (75 MHz, CDCl₃) δ = 161.9, 154.9, 145.6, 138.6, 137.2, 132.3, 132.1, 130.6, 130.1, 129.4, 129.3, 129.2, 127.4, 126.8, 123.1, 114.3, 55.5; mass (ES⁺) *m/z* 353.3 [(M+1)⁺]; Anal. Calcd for C₂₂H₁₆N₄O: C, 74.98; H, 4.58; N, 15.90. Found: C, 74.82; H, 4.67; N, 15.84.

6,9-Diphenylimidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine (7j):

Yield: 88%; yellow solid; mp 141-142 °C; R_f = 0.66 (3:7, EtOAc/Hexane); IR (KBr) ν_{max} 3053, 2923, 2856, 1647 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ = 8.34-8.31 (m, 1 H, ArH), 8.30 (s, 1 H, ArH), 8.08-8.02 (m, 3 H, ArH), 7.93-7.88 (m, 2 H, ArH), 7.62-7.59 (m, 3 H, ArH), 7.52-7.44 (m, 4 H, ArH); ¹³C NMR (50 MHz, CDCl₃) δ = 155.7, 146.1, 145.9, 138.8, 137.6, 137.1, 132.4, 132.2, 131.0, 130.7, 129.5,

129.4, 129.1, 128.6, 127.6, 127.0, 123.2; mass (ES⁺) *m/z* 323.4 [(M+1)⁺]; Anal. Calcd for C₂₁H₁₄N₄: C, 78.24; H, 4.38; N, 17.38. Found: C, 78.35; H, 4.43; N, 17.22.

6-Ethyl-9-phenylimidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine (7k):

Yield: 80%; yellow solid; mp 85-87 °C; R_f = 0.46 (2:3, EtOAc/Hexane); IR (KBr) ν_{max} 3021, 2978, 2855, 1603 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 8.27 (dd, *J* = 4.6, 1.7 Hz, 1 H, ArH), 8.20 (dd, *J* = 8.0, 1.7 Hz, 1 H, ArH), 7.95 (s, 1 H, ArH), 7.89-7.86 (m, 2 H, ArH), 7.49-7.41 (m, 4 H, ArH), 3.10 (q, *J* = 7.6 Hz, 6 H, CH₂), 1.50 (t, *J* = 7.6 Hz, 3 H, CH₃); ¹³C NMR (50 MHz, CDCl₃) δ = 160.0, 145.7, 137.0, 132.2, 132.1, 130.7, 129.3, 127.5, 127.3, 127.2, 123.0, 28.8, 12.3; mass (ES⁺) *m/z* 275.3 [(M+1)⁺]; Anal. Calcd for C₁₇H₁₄N₄: C, 74.43; H, 5.14; N, 20.42. Found: C, 74.37; H, 5.08; N, 20.55.

6-(4-Bromophenyl)-7-methyl-9-phenylimidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine (7l):

Yield: 89%; yellow solid; mp 220-221 °C; R_f = 0.57 (3:7, EtOAc/Hexane); IR (KBr) ν_{max} 3021, 2934, 2848, 1597 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 8.25 (dd, *J* = 4.6, 1.7 Hz, 2 H, ArH), 8.20 (dd, *J* = 7.9, 1.7 Hz, 1 H, ArH), 7.87-7.84 (m, 2 H, ArH), 7.71 (d, *J* = 8.4 Hz, 1 H, ArH), 7.56 (d, *J* = 8.4 Hz, 2 H, ArH), 7.49-7.39 (m, 4 H, ArH), 2.22 (s, 3 H, CH₃); ¹³C NMR (75 MHz, CDCl₃) δ = 156.4, 146.2, 144.5, 139.2, 138.8, 137.2, 136.8, 132.2, 132.0, 130.6, 130.5, 129.4, 127.6, 124.6, 123.2, 123.1, 16.5; mass (ES⁺) *m/z* 415.3 [(M+1)⁺]; Anal. Calcd for C₂₂H₁₅BrN₄: C, 63.63; H, 3.64; N, 13.49. Found: C, 63.56; H, 3.72; N, 13.37.

7-Methyl-6-(4-nitrophenyl)-9-phenylimidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine (7m):

Yield: 90%; yellow solid; mp 245-247 °C; R_f = 0.64 (2:3, EtOAc/Hexane); IR (KBr) ν_{max} 3022, 2926, 2857, 1592, 1519, 1351 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 8.44 (d, *J* = 8.7 Hz, 2 H, ArH), 8.30 (dd, *J* = 4.6, 1.7 Hz, 1 H, ArH), 8.22 (dd, *J* = 8.0, 1.7 Hz, 1 H, ArH), 7.90-7.85 (m, 4 H, ArH), 7.50-7.43 (m, 4 H, ArH), 2.20 (s, 3 H, CH₃); ¹³C NMR (75 MHz, CDCl₃) δ = 155.1, 148.9, 146.7, 144.8, 143.9, 139.1, 138.6, 137.4, 131.7, 130.6, 130.1, 129.6, 127.6, 124.0, 123.3, 122.9, 16.5; mass (ES⁺) *m/z* 382.2 [(M+1)⁺]; Anal. Calcd for C₂₂H₁₅N₅O₂: C, 69.28; H, 3.96; N, 18.36. Found: C, 69.36; H, 3.85; N, 18.43.

General Procedure for the synthesis of 5,6-Dihydroimidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine (8):

A mixture of amine **2a** (202 mg, 1 mmol) and acetophenone (120 μL, 1 mmol) was refluxed in 1% TFA in toluene until the disappearance of the starting material on TLC. The solvent was then evaporated, and the residue so obtained was basified with aq. NaHCO₃. It was then extracted with ethyl acetate (2 x 30 mL), washed with brine (10 mL), and dried over anhydrous Na₂SO₄. The ethyl acetate was evaporated to dryness under reduced pressure. The residue was purified by silica gel chromatography using hexane-ethyl acetate (40:60 v/v) to afford **8a** as white solid.

9-Ethyl-6,7-dimethyl-6-phenyl-5,6-dihydroimidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine (8a):

Yield: 72%; white solid; mp 170-172 °C; R_f = 0.37 (1:19, MeOH/CHCl₃); IR (KBr) ν_{max} 3019, 2975, 2934, 2858, 1589 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 7.86 (dd, *J* = 4.6, 1.6 Hz, 1 H, ArH), 7.43-7.40 (m, 2 H, ArH), 7.36-7.28 (m, 3 H, ArH), 7.03-6.93 (m, 2 H, ArH), 4.23 (brs, 1 H, NH), 3.40-3.31 (m, 2 H, CH₂), 1.90-1.89 (m, 6 H, 2 x CH₃), 1.38 (t, *J* = 7.4 Hz, 3 H, CH₃); ¹³C NMR (75 MHz, CDCl₃) δ = 147.8, 144.9, 138.3, 137.7, 131.2, 130.1, 128.6, 127.8, 126.7, 126.6, 122.0, 121.2, 57.1, 28.2, 24.1, 13.7, 12.5; mass (ES⁺) *m/z* 305.3 [(M+1)⁺]; Anal. Calcd for C₁₉H₂₀N₄: C, 74.97; H, 6.62; N, 18.41. Found: C, 74.89; H, 6.74; N, 18.37.

6,9-Diethyl-6,7-dimethyl-5,6-dihydroimidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine (8b):

Yield: 82%; white solid; mp 135-138 °C; R_f = 0.46 (1:19, MeOH/CHCl₃); IR (KBr) ν_{max} 3021, 2927, 2866, 1592 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 7.82-7.81 (m, 1 H, ArH), 6.98-6.90 (m, 2 H, ArH), 3.66 (brs, 1 H, NH), 3.31 (q, *J* = 7.3 Hz, 2 H, CH₂), 2.29 (s, 3 H, CH₃), 1.70-1.63 (m, 2 H, CH₂), 1.55 (s, 3 H, CH₃), 1.35 (t, *J* = 7.3 Hz, 3 H, CH₃), 0.88 (t, *J* = 7.3 Hz, 3 H, CH₃); ¹³C NMR (75 MHz, CDCl₃) δ = 147.8, 137.8, 137.0, 131.5, 129.0, 125.8, 121.4, 121.2, 55.1, 34.8, 27.3, 24.2, 14.4, 12.6, 8.7; mass (ES⁺) *m/z* 257.2 [(M+1)⁺]; Anal. Calcd for C₁₅H₂₀N₄: C, 70.28; H, 7.86; N, 21.86. Found: C, 70.34; H, 7.75; N, 21.91.

9-Ethyl-6,6,7-trimethyl-5,6-dihydroimidazo[1,5-*a*]pyrido[3,2-*e*]pyrazine (8c):

Yield: 82%; white solid; mp 141-143 °C; R_f = 0.39 (1:19, MeOH/CHCl₃); IR (KBr) ν_{max} 3018, 2969, 2930, 2856, 1589 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 7.86-7.84 (m, 1 H, ArH), 6.98-6.95 (m, 2 H,

ArH), 3.67 (brs, 1 H, NH), 3.31 (q, $J = 7.5$ Hz, 2 H, CH₂), 2.31 (s, 3 H, CH₃), 1.55 (s, 6 H, 2 x CH₃), 1.34 (t, $J = 7.5$ Hz, 3 H, CH₃); ¹³C NMR (75 MHz, CDCl₃) $\delta = 147.6, 138.0, 137.4, 131.3, 128.2, 127.2, 121.8, 121.2, 51.9, 29.4, 24.0, 14.3, 12.6$; mass (ES⁺) m/z 243.3 [(M+1)⁺]; Anal. Calcd for C₁₄H₁₈N₄: C, 69.39; H, 7.49; N, 23.12. Found: C, 69.44; H, 7.37; N, 23.19.

9'-Ethyl-7'-methyl-5'H-spiro[cyclohexane-1,6'-imidazo[1,5-a]pyrido[3,2-e]pyrazine] (8d):

Yield: 82%; yellow white solid; mp 188-190 °C; $R_f = 0.47$ (1:19, MeOH/CHCl₃); IR (KBr) ν_{\max} 3018, 2938, 2856, 1587 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) $\delta = 7.85-7.83$ (m, 1 H, ArH), 7.05-7.02 (m, 1 H, ArH), 6.96-6.92 (m, 1 H, ArH), 4.44 (brs, 1 H, NH), 3.30 (q, $J = 7.4$ Hz, 2 H, CH₂), 2.35 (s, 3 H, CH₃), 1.94-1.17 (m, 8 H, CH₂), 1.48-1.26 (m, 5 H, CH₂, CH₃); ¹³C NMR (75 MHz, CDCl₃) $\delta = 147.4, 138.6, 137.5, 130.6, 128.2, 127.9, 122.0, 121.1, 53.3, 35.0, 25.0, 24.1, 21.2, 15.1, 12.6$; mass (ES⁺) m/z 283.3 [(M+1)⁺]; Anal. Calcd for C₁₇H₂₂N₄: C, 72.31; H, 7.85; N, 19.84. Found: C, 72.24; H, 7.79; N, 19.97.

9'-Ethyl-7'-methyl-5'H-spiro[cyclopentane-1,6'-imidazo[1,5-a]pyrido[3,2-e]pyrazine] (8e):

Yield: 82%; white solid; mp 175-177 °C; $R_f = 0.38$ (1:1, EtOAc/Hexane); IR (KBr) ν_{\max} 3020, 2934, 2876, 1587 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) $\delta = 7.87-7.83$ (m, 1 H, ArH), 6.97-6.94 (m, 2 H, ArH), 3.92 (brs, 1 H, NH), 3.31 (q, $J = 7.4$ Hz, 2 H, CH₂), 2.29 (s, 3 H, CH₃), 2.24-2.18 (m, 2 H, CH₂), 1.87-1.82 (m, 6 H, 3 x CH₂), 1.34 (t, $J = 7.4$ Hz, 3 H, CH₃); ¹³C NMR (50 MHz, CDCl₃) $\delta = 148.0, 139.0, 137.9, 131.7, 128.2, 127.3, 122.2, 121.3, 62.6, 39.7, 24.3, 24.2, 14.5, 12.9$; mass (ES⁺) m/z 269.3 [(M+1)⁺]; Anal. Calcd for C₁₆H₂₀N₄: C, 71.61; H, 7.51; N, 20.88. Found: C, 71.76; H, 7.48; N, 20.76.

6,6-Dimethyl-9-phenyl-5,6-dihydroimidazo[1,5-a]pyrido[3,2-e]pyrazine (8f):

Yield: 94%; white solid; mp 111-113 °C; $R_f = 0.40$ (1:1, EtOAc/Hexane); IR (KBr) ν_{\max} 3020, 2928, 2846, 1587 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) $\delta = 7.65-7.62$ (m, 3 H, ArH), 7.38-7.36 (m, 3 H, ArH), 7.06 (dd, $J = 7.7, 1.4$ Hz, 1 H, ArH), 6.97-6.93 (m, 2 H, ArH), 3.86 (brs, 1 H, NH), 1.58 (s, 6 H, 2 x CH₃); ¹³C NMR (75 MHz, CDCl₃) $\delta = 145.1, 137.3, 137.0, 136.0, 132.4, 132.0, 129.7, 128.2, 127.2, 122.9, 122.1, 121.1, 51.2, 29.0$; mass (ES⁺) m/z 277.3 [(M+1)⁺]; Anal. Calcd for C₁₇H₁₆N₄: C, 73.89; H, 5.84; N, 20.27. Found: C, 73.82; H, 5.78; N, 20.40.

6-Ethyl-6-methyl-9-phenyl-5,6-dihydroimidazo[1,5-a]pyrido[3,2-e]pyrazine (8g):

Yield: 88%; white solid; mp 117-120 °C; $R_f = 0.37$ (2:3, EtOAc/Hexane); IR (KBr) ν_{\max} 3019, 2971, 2929, 2858, 1590 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) $\delta = 7.67-7.60$ (m, 3 H, ArH), 7.39-7.36 (m, 3 H, ArH), 7.06 (dd, $J = 7.9, 1.5$ Hz, 1 H, ArH), 6.98-6.92 (m, 2 H, ArH), 3.91 (brs, 1 H, NH), 1.78 (q, $J = 7.2$ Hz, 2 H, CH₂), 1.56 (s, 3 H, CH₃), 0.94 (t, $J = 7.4$ Hz, 3 H, CH₃); ¹³C NMR (50 MHz, CDCl₃) $\delta = 145.4, 137.3, 134.8, 132.5, 132.2, 129.9, 128.5, 127.5, 122.8, 122.4, 54.6, 34.4, 26.5, 8.8$; mass (ES⁺) m/z 291.3 [(M+1)⁺]; Anal. Calcd for C₁₈H₁₈N₄: C, 74.46; H, 6.25; N, 19.30. Found: C, 74.34; H, 6.32; N, 19.34.

9'-Phenyl-5'H-spiro[cyclohexane-1,6'-imidazo[1,5-a]pyrido[3,2-e]pyrazine] (8h):

Yield: 93%; white solid; mp 192-194 °C; $R_f = 0.29$ (3:7, EtOAc/Hexane); IR (KBr) ν_{\max} 3025, 2928, 2865, 1591 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) $\delta = 7.65-7.62$ (m, 3 H, ArH), 7.38-7.36 (m, 3 H, ArH), 7.11 (dd, $J = 7.7, 1.5$ Hz, 1 H, ArH), 7.02 (s, 1 H, ArH), 6.98-6.94 (m, 1 H, ArH), 4.33 (brs, 1 H, NH), 1.93-1.72 (m, 6 H, 3 x CH₂), 1.60-1.41 (m, 4 H, 2 x CH₂); ¹³C NMR (75 MHz, CDCl₃) $\delta = 145.2, 137.7, 136.4, 132.4, 131.5, 129.8, 128.4, 127.4, 123.1, 122.1, 121.8, 52.9, 36.2, 24.9, 21.6$; mass (ES⁺) m/z 317.3 [(M+1)⁺]; Anal. Calcd for C₂₀H₂₀N₄: C, 75.92; H, 6.37; N, 17.71. Found: C, 75.86; H, 6.48; N, 17.66.

Synthesis of 6-Chloro-N,N-diethyl-5-nitropyrimidin-4-amine (10):

To a solution of 4,6-dichloro-5-nitropyrimidine **9** (2.00 g, 10.4 mmol) in anhydrous THF (40 mL) was added dropwise a solution of diethylamine (879 μ L, 8.5 mmol) and triethylamine (2.1 mL, 15.6 mmol) in anhydrous THF (20 mL) at 0 °C. The reaction mixture was stirred for 1 h at 0 °C. After being warmed to room temperature, the solvent was concentrated in vacuo. The residue was dissolved in EtOAc (50 mL), washed with 1N HCl (30 mL) and brine (30 mL), and dried over anhydrous Na₂SO₄. The organic solvent was concentrated in vacuo and the residue was purified by column chromatography on a silica gel column (Hexane/EtOAc 20:1, v/v) provided the desired product **10**.

6-Chloro-N,N-diethyl-5-nitropyrimidin-4-amine (10):

Yield: 88%; yellow oil; $R_f = 0.42$ (1:19, EtOAc/Hexane); IR (Neat) ν_{\max} 3020, 2938, 2851, 1530, 1354 cm^{-1} ; ^1H NMR (200 MHz, CDCl_3) $\delta = 8.35$ (s, 1 H, ArH), 3.49 (q, $J = 7.1$ Hz, 4 H, 2 x CH_2), 1.23 (t, $J = 7.1$ Hz, 6 H, 2 x CH_3); ^{13}C NMR (50 MHz, CDCl_3) $\delta = 156.2, 152.9, 152.3, 44.2, 12.8$; mass (ES^+) m/z 231.2 [(M+1) $^+$]; Anal. Calcd for $\text{C}_8\text{H}_{11}\text{ClN}_4\text{O}_2$: C, 41.66; H, 4.81; N, 24.29. Found: C, 41.72; H, 4.69; N, 24.38.

General Procedure for the Synthesis of Nitro Derivative (11):

To a solution of 6-chloro-*N,N*-diethyl-5-nitropyrimidin-4-amine **10** (1.15 g, 5 mmol) and triethylamine (1.04 mL, 7.5 mmol) in anhydrous THF (25 mL) was added a solution of 2-methyl-1*H*-imidazole (410 mg, 5 mmol) in anhydrous THF (5 mL) at rt. The reaction mixture was refluxed for 16 h. After being cooled to room temperature, the solvent was concentrated in vacuo. The residue was dissolved in ethyl acetate (80 mL), washed water (2 x 30 mL) and brine (2 x 30 mL), and dried over anhydrous Na_2SO_4 . The organic solvent was concentrated in vacuo and the residue was purified by column chromatography on a silica gel column using neat chloroform to afford the desired product **11a**.

N,N-Diethyl-6-(2-methyl-1*H*-imidazol-1-yl)-5-nitropyrimidin-4-amine (11a)

Yield: 68%; yellow oil; $R_f = 0.47$ (1:19, MeOH/ CHCl_3); IR (Neat) ν_{\max} 3020, 2926, 2846, 1589, 1532, 1358 cm^{-1} ; ^1H NMR (200 MHz, CDCl_3) $\delta = 8.55$ (s, 1 H, ArH), 6.98-6.96 (m, 2 H, ArH), 3.52 (q, $J = 7.1$ Hz, 4 H, 2 x CH_2), 2.38 (s, 3 H, CH_3), 1.26 (t, $J = 7.1$ Hz, 6 H, 2 x CH_3); ^{13}C NMR (75 MHz, DMSO) $\delta = 157.5, 153.3, 150.1, 144.9, 128.0, 127.4, 120.4, 44.0, 13.0, 12.3$; mass (ES^+) m/z 277.1 [(M+1) $^+$]; Anal. Calcd for $\text{C}_{12}\text{H}_{16}\text{N}_6\text{O}_2$: C, 52.16; H, 5.84; N, 30.42. Found: C, 52.22; H, 5.72; N, 30.56.

N,N-diethyl-6-(2-ethyl-4-methyl-1*H*-imidazol-1-yl)-5-nitropyrimidin-4-amine (11b):

Yield: 66%; yellow oil; $R_f = 0.50$ (1:19, MeOH/ CHCl_3); IR (Neat) ν_{\max} 3029, 2926, 2852, 1528, 1351 cm^{-1} ; ^1H NMR (200 MHz, CDCl_3) $\delta = 8.52$ (s, 1 H, ArH), 6.64 (d, $J = 1.0$ Hz, 1 H, ArH), 3.52 (q, $J = 7.1$ Hz, 4 H, 2 x CH_2), 2.68 (q, $J = 7.6$ Hz, 2 H, CH_2), 2.20 (d, $J = 1.0$ Hz, 3 H, CH_3), 1.29-1.21 (m, 9 H, 3 x CH_3); ^{13}C NMR (50 MHz, CDCl_3) $\delta = 157.1, 153.5, 150.5, 150.1, 137.7, 115.7, 44.3, 20.9, 13.5, 12.7, 12.2$; mass (ES^+) m/z 305.3 [(M+1) $^+$]; Anal. Calcd for $\text{C}_{14}\text{H}_{20}\text{N}_6\text{O}_2$: C, 55.25; H, 6.62; N, 27.61. Found: C, 55.31; H, 6.68; N, 27.72.

General Procedure for the Synthesis of Amine Derivative (3):

A solution of **11a** (552 mg, 2 mmol) and Fe (440 mg, 8 mmol) in acidic ethanol (1:4 HCl/EtOH) was refluxed under nitrogen atmosphere for 1 h. The solution was allowed to cool down and then poured into ice, the pH is made slightly basic (pH 8) by addition of 5% aqueous NaHCO_3 . The ethyl acetate (50 mL) was added to the mixture and filtered through a bed of celite. The organic layer was finally washed with water (50 mL), brine (50 mL) and dried over anhydrous Na_2SO_4 . The organic layer was evaporated to dryness under reduced pressure. The crude product was purified on a silica gel column using chloroform-methanol (19:1, v/v) as eluent to afford **3a**.

N,N'-Diethyl-6-(2-methyl-1*H*-imidazol-1-yl)pyrimidine-4,5-diamine (3a):

Yield: 85%; white solid; mp 114-115 °C; $R_f = 0.29$ (1:19, MeOH/ CHCl_3); IR (KBr) ν_{\max} 3342, 3208, 2927, 2848, 1631 cm^{-1} ; ^1H NMR (200 MHz, CDCl_3) $\delta = 8.26$ (s, 1 H, ArH), 7.08-7.05 (m, 2 H, ArH), 3.49-3.38 (m, 6 H, 2 x CH_2 , NH_2), 2.37 (s, 3 H, CH_3), 1.18 (t, $J = 7.1$ Hz, 6 H, 2 x CH_3); ^{13}C NMR (50 MHz, CDCl_3) $\delta = 157.9, 147.8, 145.6, 141.2, 128.6, 126.0, 118.9, 43.1, 13.4$; mass (ES^+) m/z 247.4 [(M+1) $^+$]; Anal. Calcd for $\text{C}_{12}\text{H}_{18}\text{N}_6$: C, 58.51; H, 7.37; N, 34.12. Found: C, 58.41; H, 7.41; N, 34.18.

N,N'-diethyl-6-(2-ethyl-4-methyl-1*H*-imidazol-1-yl)pyrimidine-4,5-diamine (3b):

Yield: 83% white solid; mp 92-93 °C; $R_f = 0.38$ (1:19, MeOH/ CHCl_3); IR (KBr) ν_{\max} 3349, 3205, 2968, 2927, 2849, 1631 cm^{-1} ; ^1H NMR (200 MHz, CDCl_3) $\delta = 8.27$ (s, 1 H, ArH), 6.77 (d, $J = 1.0$ Hz, 1H, ArH), 3.5-3.39 (m, 6 H, 2x CH_2 , NH_2), 2.67 (q, $J = 7.6$ Hz, 2 H, CH_2), 2.25 (d, $J = 1.0$ Hz, 3 H, CH_3), 1.27-1.16 (m, 9 H, 3 x CH_3); ^{13}C NMR (50 MHz, CDCl_3) $\delta = 157.7, 149.8, 147.7, 141.4, 137.7, 126.0, 114.8, 43.0, 20.8, 13.6, 13.3, 12.3$; mass (ES^+) m/z 275.3 [(M+1) $^+$]; Anal. Calcd for $\text{C}_{14}\text{H}_{22}\text{N}_6$: C, 61.29; H, 8.08; N, 30.63. Found: C, 61.34; H, 8.13; N, 30.53.

General Procedure for the Synthesis of Imidazo[5,1-*h*]pteridine (12):

A mixture of amine **3a** (246 mg, 1 mmol) and 4-methylbenzaldehyde (120 μL , 1 mmol) was refluxed in 1% TFA in toluene until the disappearance of the starting material on TLC. Then, the reaction mixture

was treated with DDQ (1.5 mmol) for 10 min at reflux. Toluene was evaporated in vacuo, and the residue so obtained was basified with aq. NaHCO₃ and extracted with ethyl acetate (2 x 30 mL). The organic layers were washed with brine (10 mL), and dried over anhydrous Na₂SO₄. The ethyl acetate was evaporated under reduced pressure to obtain residue that after column chromatography on silica gel using hexane-ethyl acetate (60:40 v/v) afforded **12a** as white solid.

***N,N*-Diethyl-9-methyl-6-*p*-tolylimidazo[5,1-*h*]pteridin-4-amine (12a):**

Yield: 74%; yellow solid; mp 121-122 °C; R_f = 0.60 (3:7, EtOAc/Hexane); IR (KBr) ν_{max} 3037, 2984, 2930, 2852, 1550 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ = 8.40 (s, 1 H, ArH), 7.86 (d, *J* = 8.2 Hz, 2 H, ArH), 7.74 (s, 1 H, ArH), 7.34 (d, *J* = 8.2 Hz, 2 H, ArH), 4.03 (q, *J* = 6.9 Hz, 4 H, 2 x CH₂), 3.22 (s, 3 H, CH₃), 2.46 (s, 3 H, CH₃), 1.36 (t, *J* = 6.9 Hz, 6 H, 2 x CH₃); ¹³C NMR (50 MHz, CDCl₃) δ = 158.1, 153.9, 149.5, 144.2, 144.1, 140.5, 135.0, 129.5, 128.1, 125.9, 125.6, 116.2, 45.8, 21.6, 18.6, 13.7; mass (ES⁺) *m/z* 347.4 [(M+1)⁺]; Anal. Calcd for C₂₀H₂₂N₆: C, 69.34; H, 6.40; N, 24.26. Found: C, 69.28; H, 6.53; N, 24.19.

6-(4-Ethoxyphenyl)-*N,N*-diethyl-9-methylimidazo[5,1-*h*]pteridin-4-amine (12b):

Yield: 73%; yellow solid; mp 117-119 °C; R_f = 0.60 (2:3, EtOAc/Hexane); IR (KBr) ν_{max} 3022, 2976, 2929, 2848, 1589 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ = 8.40 (s, 1 H, ArH), 7.92 (d, *J* = 8.9 Hz, 2 H, ArH), 7.75 (s, 1 H, ArH), 7.03 (d, *J* = 8.9 Hz, 2 H, ArH), 4.19-3.99 (m, 6 H, 3 x CH₂), 3.22 (s, 3 H, CH₃), 1.47 (t, *J* = 7.0 Hz, 3 H, CH₃), 1.36 (t, *J* = 7.0 Hz, 6 H, 2 x CH₃); ¹³C NMR (50 MHz, CDCl₃) δ = 160.8, 158.0, 153.7, 149.0, 144.1, 130.1, 129.9, 129.6, 125.8, 125.4, 116.2, 114.6, 63.8, 45.8, 18.6, 15.0, 13.8; mass (ES⁺) *m/z* 377.3 [(M+1)⁺]; Anal. Calcd for C₂₁H₂₄N₆O: C, 67.00; H, 6.43; N, 22.32. Found: C, 67.14; H, 6.31; N, 22.23.

***N,N*-Diethyl-6-(4-methoxyphenyl)-9-methylimidazo[5,1-*h*]pteridin-4-amine (12c):**

Yield: 75%; yellow solid; mp 129-130 °C; R_f = 0.38 (3:7, EtOAc/Hexane); IR (KBr) ν_{max} 3050, 2926, 2857, 1607 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ = 8.40 (s, 1 H, ArH), 7.93 (d, *J* = 8.9 Hz, 2 H, ArH), 7.74 (s, 1 H, ArH), 7.05 (d, *J* = 8.9 Hz, 2 H, ArH), 4.04 (q, *J* = 7.0 Hz, 6 H, 3 x CH₂), 3.90 (s, 3 H, CH₃), 3.22 (s, 3 H, CH₃), 1.36 (t, *J* = 7.0 Hz, 3 H, CH₃), 1.36 (t, *J* = 7.0 Hz, 6 H, 2 x CH₃); ¹³C NMR (50 MHz, CDCl₃) δ = 161.4, 158.0, 153.8, 149.0, 130.3, 129.7, 125.8, 125.5, 116.2, 114.2, 55.6, 45.8, 18.7, 13.8; mass (ES⁺) *m/z* 363.4 [(M+1)⁺]; Anal. Calcd for C₂₀H₂₂N₆O: C, 66.28; H, 6.12; N, 23.19. Found: C, 66.16; H, 6.24; N, 23.25.

2-(4-(Diethylamino)-9-methylimidazo[5,1-*h*]pteridin-6-yl)phenol (12d):

Yield: 70%; yellow solid; mp 154-156 °C; R_f = 0.47 (3:7, EtOAc/Hexane); IR (KBr) ν_{max} 3458, 2978, 2927, 2859, 1598 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ = 10.96 (brs, 1 H, OH), 8.45 (s, 1 H, ArH), 8.03-7.93 (m, 3 H, ArH), 7.47-7.38 (m, 1 H, ArH), 7.14-7.01 (m, 3 H, ArH), 3.96 (q, *J* = 7.0 Hz, 4 H, 2 x CH₂), 3.23 (s, 3 H, CH₃), 1.36 (t, *J* = 7.0 Hz, 6 H, 2 x CH₃); ¹³C NMR (50 MHz, CDCl₃) δ = 158.2, 157.6, 154.1, 144.7, 133.0, 132.4, 129.4, 129.0, 128.2, 125.4, 119.9, 119.7, 118.1, 117.9, 45.4, 18.9, 13.5; mass (ES⁺) *m/z* 349.3 [(M+1)⁺]; Anal. Calcd for C₁₉H₂₀N₆O: C, 65.50; H, 5.79; N, 24.12. Found: C, 65.41; H, 5.86; N, 24.21.

***N,N*-diethyl-9-methyl-6-phenylimidazo[5,1-*h*]pteridin-4-amine (12e):**

Yield: 72%; yellow solid; mp 137-139 °C; R_f = 0.69 (2:3, EtOAc/Hexane); IR (KBr) ν_{max} 3021, 2976, 2932, 2853, 1550 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ = 8.41 (s, 1 H, ArH), 7.98-7.93 (m, 2 H, ArH), 7.76 (s, 1 H, ArH), 7.55 (m, 3 H, ArH), 4.04 (q, *J* = 6.8 Hz, 4 H, 2 x CH₂), 3.23 (s, 3 H, CH₃), 1.36 (t, *J* = 7.0 Hz, 6 H, 2 x CH₃); ¹³C NMR (50 MHz, CDCl₃) δ = 158.1, 154.2, 149.5, 144.4, 144.2, 137.7, 130.4, 128.9, 128.2, 126.0, 125.6, 116.2, 45.9, 18.7, 13.8; mass (ES⁺) *m/z* 333.3 [(M+1)⁺]; Anal. Calcd for C₁₉H₂₀N₆: C, 68.65; H, 6.06; N, 25.28. Found: C, 68.48; H, 6.11; N, 25.41.

***N,N*-Diethyl-9-methyl-6-(4-nitrophenyl)imidazo[5,1-*h*]pteridin-4-amine (12f):**

Yield: 71%; red solid; mp 201-202 °C; R_f = 0.56 (2:3, EtOAc/Hexane); IR (KBr) ν_{max} 3021, 2976, 2928, 2846, 1550, 1348 cm⁻¹. ¹H NMR (200 MHz, CDCl₃) δ = 8.44-8.38 (m, 3 H, ArH), 8.13 (d, *J* = 8.7 Hz, 2 H, ArH), 7.74 (s, 1 H, ArH), 4.03 (d, *J* = 6.6 Hz, 4 H, 2 x CH₂), 3.24 (s, 3 H, CH₃), 1.36 (t, *J* = 6.8 Hz, 6 H, 2 x CH₃); mass (ES⁺) *m/z* 378.3 [(M+1)⁺]; Anal. Calcd for C₁₉H₁₉N₇O₂: C, 60.47; H, 5.07; N, 25.98. Found: C, 60.32; H, 5.14; N, 25.81.

6-(4-Chlorophenyl)-*N,N*-diethyl-9-methylimidazo[5,1-*h*]pteridin-4-amine (12g):

Yield: 70%; yellow solid; mp 182-183 °C; $R_f = 0.61$ (2:3, EtOAc/Hexane); IR (KBr) ν_{\max} 2977, 2927, 2861, 1634, 1548 cm^{-1} ; $^1\text{H NMR}$ (200 MHz, CDCl_3) $\delta = 8.41$ (s, 1H, ArH), 7.90 (d, $J = 8.7$ Hz, 2 H, ArH), 7.71 (s, 1 H, ArH), 7.51 (d, $J = 8.7$ Hz, 2 H, ArH), 4.02 (q, $J = 6.8$ Hz, 4 H, 2 x CH_2), 3.22 (s, 3 H, CH_3), 1.35 (t, $J = 6.9$ Hz, 6 H, 2 x CH_3); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) $\delta = 154.3, 148.2, 144.4, 136.3, 136.1, 129.4, 129.1, 125.7, 125.4, 116.0, 45.8, 18.6, 13.7$; mass (ES^+) m/z 367.4 [(M+1) $^+$]; Anal. Calcd for $\text{C}_{19}\text{H}_{19}\text{ClN}_6$: C, 62.21; H, 5.22; N, 22.91. Found: C, 62.33; H, 5.08; N, 22.82.

6-(4-Bromophenyl)-*N,N*-diethyl-9-methylimidazo[5,1-*h*]pteridin-4-amine (12h):

Yield: 73%; yellow solid; mp 180-181 °C; $R_f = 0.56$ (3:7, EtOAc/Hexane); IR (KBr) ν_{\max} 3037, 2984, 2926, 2864, 1586 cm^{-1} ; $^1\text{H NMR}$ (200 MHz, CDCl_3) $\delta = 8.41$ (s, 1 H, ArH), 7.83 (d, $J = 8.7$ Hz, 2 H, ArH), 7.71 (s, 1 H, ArH), 7.17 (d, $J = 8.2$ Hz, 2 H, ArH), 4.02 (q, $J = 6.6$ Hz, 4 H, 2 x CH_2), 3.22 (s, 3 H, CH_3), 1.35 (t, $J = 6.9$ Hz, 6 H, 2 x CH_3); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) $\delta = 158.1, 154.3, 148.3, 144.5, 144.4, 136.6, 132.1, 129.7, 125.6, 125.4, 124.7, 116.0, 45.9, 18.7, 13.8$; mass (ES^+) m/z 411.3 [(M+1) $^+$]; Anal. Calcd for $\text{C}_{19}\text{H}_{19}\text{BrN}_6$: C, 55.48; H, 4.66; N, 20.43. Found: C, 55.57; H, 4.71; N, 20.56.

***N,N*,6-Triethyl-9-methylimidazo[5,1-*h*]pteridin-4-amine (12i):**

Yield: 52%; yellow solid; mp 77-79 °C; $R_f = 0.68$ (1:9, MeOH/ CHCl_3); IR (KBr) ν_{\max} 2972, 2933, 2851, 1561 cm^{-1} ; $^1\text{H NMR}$ (200 MHz, CDCl_3) $\delta = 8.37$ (s, 1 H, ArH), 7.56 (s, 1 H, ArH), 4.01 (q, $J = 6.9$ Hz, 4 H, 2 x CH_2), 3.16 (s, 3 H, CH_3), 2.95 (q, $J = 7.4$ Hz, 2 H, CH_2), 1.40-1.25 (m, 9 H, 3 x CH_3); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) $\delta = 157.9, 153.7, 153.5, 144.4, 143.8, 126.7, 123.3, 115.7, 45.7, 27.9, 18.4, 13.8, 11.0$; mass (ES^+) m/z 285.3 [(M+1) $^+$]; Anal. Calcd for $\text{C}_{15}\text{H}_{20}\text{N}_6$: C, 63.36; H, 7.09; N, 29.55. Found: C, 63.43; H, 7.14; N, 29.43.

***N,N*,9-Triethyl-6-(4-methoxyphenyl)-7-methylimidazo[5,1-*h*]pteridin-4-amine (12j):**

Yield: 75%; yellow solid; mp 129-130 °C; $R_f = 0.57$ (3:7, EtOAc/Hexane); IR (KBr) ν_{\max} 3032, 2978, 2927, 2849, 1553 cm^{-1} ; $^1\text{H NMR}$ (200 MHz, CDCl_3) $\delta = 8.37$ (s, 1 H, ArH), 7.55 (d, $J = 8.7$ Hz, 2 H, ArH), 7.00 (d, $J = 8.8$ Hz, 2 H, ArH), 3.96 (q, $J = 7.0$ Hz, 4 H, 2 x CH_2), 3.89 (s, 3 H, CH_3), 3.66 (q, $J = 7.4$ Hz, 2 H, CH_2), 2.24 (s, 3 H, CH_3), 1.45 (t, $J = 7.4$ Hz, 3 H, CH_3), 1.30 (t, $J = 6.9$ Hz, 6 H, 2 x CH_3); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) $\delta = 160.9, 158.1, 153.8, 151.4, 147.7, 144.2, 134.6, 131.0, 130.5, 122.5, 116.0, 113.7, 55.6, 45.8, 24.8, 16.5, 13.8, 13.3$; mass (ES^+) m/z 391.4 [(M+1) $^+$]; Anal. Calcd for $\text{C}_{22}\text{H}_{26}\text{N}_6\text{O}$: C, 67.67; H, 6.71; N, 21.52. Found: C, 67.76; H, 6.59; N, 21.68.

4-(4-(Diethylamino)-9-ethyl-7-methylimidazo[5,1-*h*]pteridin-6-yl)phenol (12k):

Yield: 73%; yellow solid; mp 226-227 °C; $R_f = 0.47$ (2:3, EtOAc/Hexane); IR (KBr) ν_{\max} 3407, 2977, 2929, 2856, 1558 cm^{-1} ; $^1\text{H NMR}$ (200 MHz, CDCl_3) $\delta = 9.13$ (brs, 1 H, OH), 8.36 (s, 1 H, ArH), 7.46 (d, $J = 8.7$ Hz, 2 H, ArH), 6.96 (d, $J = 8.7$ Hz, 2 H, ArH), 3.97 (q, $J = 6.8$ Hz, 4 H, 2 x CH_2), 3.66 (q, $J = 7.4$ Hz, 2 H, CH_2), 2.25 (s, 3 H, CH_3), 1.45 (t, $J = 7.4$ Hz, 3 H, CH_3), 1.30 (t, $J = 6.9$ Hz, 6 H, 2 x CH_3); mass (ES^+) m/z 377.4 [(M+1) $^+$]; Anal. Calcd for $\text{C}_{21}\text{H}_{24}\text{N}_6\text{O}$: C, 67.00; H, 6.43; N, 22.32. Found: C, 67.12; H, 6.54; N, 22.56.

2-(4-(Diethylamino)-9-ethyl-7-methylimidazo[5,1-*h*]pteridin-6-yl)phenol (12l):

Yield: 68%; yellow solid; mp 183-185 °C; $R_f = 0.60$ (2:3, EtOAc/Hexane); IR (KBr) ν_{\max} 3415, 3020, 2975, 2930, 2851, 1580 cm^{-1} ; $^1\text{H NMR}$ (200 MHz, CDCl_3) $\delta = 8.88$ (brs, 1 H, OH), 8.38 (s, 1 H, ArH), 7.42-7.35 (m, 2 H, ArH), 7.10-7.00 (m, 2 H, ArH), 3.92 (q, $J = 7.0$ Hz, 4 H, 2 x CH_2), 3.65 (q, $J = 7.3$ Hz, 2 H, CH_2), 2.27 (s, 3 H, CH_3), 1.44 (t, $J = 7.4$ Hz, 3H, CH_3), 1.29 (t, $J = 7.0$ Hz, 6H, 2 x CH_3); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) $\delta = 157.9, 155.6, 154.1, 150.5, 148.0, 144.5, 135.6, 131.5, 130.8, 123.1, 122.5, 119.5, 116.9, 115.4, 45.8, 24.7, 15.9, 13.6, 13.2$; mass (ES^+) m/z 377.3 [(M+1) $^+$]; Anal. Calcd for $\text{C}_{21}\text{H}_{24}\text{N}_6\text{O}$: C, 67.00; H, 6.43; N, 22.32. Found: C, 67.12; H, 6.31; N, 22.36.

***N,N*,9-Triethyl-7-methyl-6-phenylimidazo[5,1-*h*]pteridin-4-amine (12m):**

Yield: 70%; yellow solid; mp 80-82 °C; $R_f = 0.68$ (3:7, EtOAc/Hexane); IR (KBr) ν_{\max} 3021, 2979, 2929, 2861, 1559 cm^{-1} ; $^1\text{H NMR}$ (200 MHz, CDCl_3) $\delta = 8.39$ (s, 1 H, ArH), 7.61-7.57 (m, 2 H, ArH), 7.51-7.47 (m, 3 H, ArH), 3.97 (q, $J = 6.9$ Hz, 4 H, 2 x CH_2), 3.68 (q, $J = 7.4$ Hz, 2 H, CH_2), 2.18 (s, 3 H, CH_3), 1.46 (t, $J = 7.4$ Hz, 3 H, CH_3), 1.29 (t, $J = 6.9$ Hz, 6 H, 2 x CH_3); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) $\delta = 158.1, 154.0, 151.6, 147.7, 144.3, 138.4, 134.6, 129.5, 128.9, 128.2, 122.3, 115.9, 45.8, 24.7, 16.2, 13.7$.

13.2; mass (ES⁺) m/z 361.4 [(M+1)⁺]; Anal. Calcd for C₂₁H₂₄N₆: C, 69.97; H, 6.71; N, 23.32. Found: C, 69.81; H, 6.83; N, 23.23.

4-(4-(Diethylamino)-9-ethyl-7-methylimidazo[5,1-*h*]pteridin-6-yl)benzotrile (12n):

Yield: 73%; yellow solid; mp 147-148 °C; R_f = 0.68 (2:3, EtOAc/Hexane); IR (KBr) ν_{\max} 3037, 2981, 2928, 2847, 2222, 1553 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ = 8.41 (s, 1 H, ArH), 7.81 (d, J = 8.4 Hz, 2 H, ArH), 7.71 (d, J = 8.2 Hz, 2 H, ArH), 3.94 (q, J = 6.8 Hz, 4 H, 2 x CH₂), 3.67 (q, J = 7.4 Hz, 2 H, CH₂), 2.18 (s, 3 H, CH₃), 1.45 (t, J = 7.4 Hz, 3 H, CH₃), 1.29 (t, J = 6.9 Hz, 6 H, 2 x CH₃); ¹³C NMR (50 MHz, CDCl₃) δ = 158.1, 154.6, 149.3, 148.2, 144.6, 142.7, 134.4, 132.2, 129.7, 121.9, 118.6, 115.7, 113.4, 45.9, 24.8, 16.4, 13.7, 13.2; mass (ES⁺) m/z 386.4 [(M+1)⁺]; Anal. Calcd for C₂₂H₂₃N₇: C, 68.55; H, 6.01; N, 25.44. Found: C, 68.43; H, 6.06; N, 25.51.

***N,N*,9-Triethyl-7-methyl-6-(4-nitrophenyl)imidazo[5,1-*h*]pteridin-4-amine (12o):** Yield: 82%; orange solid; mp 132-133 °C; R_f = 0.65 (3:7, EtOAc/Hexane); IR (KBr) ν_{\max} 3031, 2965, 2925, 2854, 1560, 1508, 1371 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ = 8.41 (s, 1 H, ArH), 8.37 (d, J = 8.8 Hz, 2 H, ArH), 7.77 (d, J = 8.8 Hz, 2 H, ArH), 3.95 (q, J = 6.9 Hz, 4H, 2 x CH₂), 3.67 (q, J = 7.4 Hz, 2 H, CH₂), 2.19 (s, 3 H, CH₃), 1.45 (t, J = 7.4 Hz, 3 H, CH₃), 1.29 (t, J = 6.9 Hz, 6H, 2 x CH₃); ¹³C NMR (50 MHz, CDCl₃) δ = 158.1, 154.7, 148.9, 148.6, 144.6, 144.5, 134.4, 130.0, 123.7, 121.9, 115.7, 45.9, 24.8, 16.5, 13.7, 13.2; mass (ES⁺) m/z 406.3 [(M+1)⁺]; Anal. Calcd for C₂₁H₂₃N₇O₂: C, 62.21; H, 5.72; N, 24.18. Found: C, 62.33; H, 5.81; N, 24.12.

6-(4-Chlorophenyl)-*N,N*,9-triethyl-7-methylimidazo[5,1-*h*]pteridin-4-amine (12p):

Yield: 73%; yellow solid; mp 112-114 °C; R_f = 0.73 (3:7, EtOAc/Hexane); IR (KBr) ν_{\max} 3046, 2984, 2928, 2849, 1552 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ = 8.39 (s, 1 H, ArH), 7.55-7.46 (m, 4 H, ArH), 3.95 (d, J = 6.6 Hz, 4 H, 2 x CH₂), 3.66 (q, J = 7.4 Hz, 2 H, CH₂), 2.21 (s, 3 H, CH₃), 1.45 (t, J = 7.4 Hz, 3 H, CH₃), 1.29 (t, J = 6.9 Hz, 6 H, 2 x CH₃); ¹³C NMR (50 MHz, CDCl₃) δ = 158.1, 154.2, 150.3, 147.9, 136.9, 135.7, 134.5, 130.4, 128.6, 122.2, 115.9, 45.8, 24.8, 16.4, 13.8, 13.3; mass (ES⁺) m/z 395.3 [(M+1)⁺]; Anal. Calcd for C₂₁H₂₃ClN₆: C, 63.87; H, 5.87; N, 21.28. Found: C, 63.77; H, 5.72; N, 21.34.

***N,N*,6,9-Tetraethyl-7-methylimidazo[5,1-*h*]pteridin-4-amine (12q):**

Yield: 55%; yellow solid; mp 112-114 °C; R_f = 0.73 (3:7, EtOAc/Hexane); IR (KBr) ν_{\max} 3046, 2979, 2933, 2849, 1559 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ = 8.34 (s, 1 H, ArH), 4.01 (q, J = 6.9 Hz, 4 H, 2 x CH₂), 3.60 (q, J = 7.4 Hz, 2 H, CH₂), 3.04 (q, J = 7.4 Hz, 2 H, CH₂), 2.70 (s, 3 H, CH₃), 1.45-1.28 (m, 12 H, 4 x CH₃); ¹³C NMR (50 MHz, CDCl₃) δ = 157.8, 154.3, 153.6, 147.0, 144.6, 133.3, 122.9, 115.7, 45.7, 29.3, 24.7, 16.0, 13.9, 13.2, 11.3; mass (ES⁺) m/z 313.3 [(M+1)⁺]; Anal. Calcd for C₁₇H₂₄N₆: C, 65.36; H, 7.74; N, 26.90. Found: C, 65.43; H, 7.81; N, 26.22.

6-Benzyl-*N,N*,9-triethyl-7-methylimidazo[5,1-*h*]pteridin-4-amine (12r):

Yield: 57%; yellow oil; R_f = 0.76 (2:3, EtOAc/Hexane); IR (KBr) ν_{\max} 3017, 2973, 2933, 2853, 1558 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ = 8.34 (s, 1 H, ArH), 7.27-7.25 (m, 5 H, ArH), 4.35 (s, 2 H, CH₂), 3.82 (q, J = 6.9 Hz, 4 H, 2 x CH₂), 3.61 (q, 2 H, J = 7.4 Hz, CH₂), 2.64 (s, 3 H, CH₃), 1.41 (t, J = 7.4 Hz, 3 H, CH₃), 1.14 (t, J = 6.9 Hz, 3 H, CH₃); ¹³C NMR (50 MHz, CDCl₃) δ = 157.7, 154.2, 153.8, 151.7, 147.3, 144.6, 137.8, 133.6, 129.3, 128.7, 126.7, 123.2, 45.7, 42.2, 24.8, 16.1, 13.6, 13.3; mass (ES⁺) m/z 375.4 [(M+1)⁺]; Anal. Calcd for C₂₂H₂₆N₆: C, 70.56; H, 7.00; N, 22.44. Found: C, 70.68; H, 7.14; N, 22.18.

General Procedure for the Synthesis of 5,6-Dihydroimidazo[5,1-*h*]pteridine (13):

A mixture of amine **3a** (246 mg, 1 mmol) and acetone (58 μ L, 1 mmol) was refluxed in 1% TFA in toluene until the disappearance of the starting material on TLC. The solvent was then evaporated, and the residue so obtained was basified with aq. NaHCO₃. It was then extracted with ethyl acetate (2 x 30 mL), washed with brine (10 mL), and dried over anhydrous Na₂SO₄. The ethyl acetate was evaporated to dryness under reduced pressure. The residue was purified by silica gel chromatography using hexane-ethyl acetate (45:55 v/v) to afford **13a** as white solid.

***N,N*-Diethyl-6,6,9-trimethyl-5,6-dihydroimidazo[5,1-*h*]pteridin-4-amine (13a):**

Yield: 51%; brown solid; mp 97-99 °C; $R_f = 0.62$ (1:9, MeOH/CHCl₃); IR (KBr) ν_{\max} 3020, 2973, 2927, 2855, 1569 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) $\delta = 8.26$ (s, 1 H, ArH), 6.69 (s, 1 H, ArH), 3.61 (brs, 1 H, NH), 3.30 (q, $J = 7.1$ Hz, 4H, 2 x CH₂), 2.82 (s, 3 H, CH₃), 1.51 (s, 6 H, 2 x CH₃), 1.11 (t, $J = 7.1$ Hz, 6 H, 2 x CH₃); ¹³C NMR (50 MHz, CDCl₃) $\delta = 156.4, 147.2, 144.7, 142.7, 133.7, 120.1, 119.3, 50.6, 43.7, 29.2, 17.2, 13.2$; mass (ES⁺) m/z 287.3 [(M+1)⁺]; Anal. Calcd for C₁₅H₂₂N₆: C, 62.91; H, 7.74; N, 29.35. Found: C, 62.86; H, 7.82; N, 29.41.

***N,N*,9-Triethyl-6,6,7-trimethyl-5,6-dihydroimidazo[5,1-*h*]pteridin-4-amine (13b):**

Yield: 58%; yellow oil; $R_f = 0.41$ (1:1, EtOAc/Hexane); IR (KBr) ν_{\max} 3020, 2975, 2931, 2849, 1583 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) $\delta = 8.25$ (s, 1 H, ArH), 3.56 (brs, 1 H, NH), 3.30 (q, $J = 7.1$ Hz, 6 H, 3 x CH₂), 2.31 (s, 3 H, CH₃), 1.55 (s, 2 H, 2 x CH₃), 1.35 (t, $J = 7.4$ Hz, 3 H, CH₃), 1.13 (t, $J = 7.1$ Hz, 6 H, 2 x CH₃); ¹³C NMR (50 MHz, CDCl₃) $\delta = 156.2, 148.3, 147.3, 142.7, 128.9, 127.1, 119.5, 51.9, 44.0, 29.4, 23.8, 14.2, 13.4, 12.7$; mass (ES⁺) m/z 315.3 [(M+1)⁺]; Anal. Calcd for C₁₇H₂₆N₆: C, 64.94; H, 8.33; N, 26.73. Found: C, 64.89; H, 8.24; N, 26.87.

***N,N*,6,9-Tetraethyl-6,7-dimethyl-5,6-dihydroimidazo[5,1-*h*]pteridin-4-amine (13c):**

Yield: 57%; yellow oil; $R_f = 0.37$ (1:1, EtOAc/Hexane); IR (KBr) ν_{\max} 3020, 2972, 2929, 2847, 1579 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) $\delta = 8.23$ (s, 1 H, ArH), 3.64 (brs, 1 H, NH), 3.39-3.17 (m, 6 H, 3 x CH₂), 2.29 (s, 3 H, CH₃), 1.87-1.63 (m, 2 H, CH₂), 1.56 (s, 3 H, CH₃), 1.35 (t, $J = 7.4$ Hz, 3 H, CH₃), 1.12 (t, $J = 7.1$ Hz, 6 H, 2 x CH₃), 0.86 (t, $J = 7.4$ Hz, 3 H, CH₃); ¹³C NMR (50 MHz, CDCl₃) $\delta = 155.7, 148.4, 146.7, 142.1, 129.7, 125.8, 120.1, 55.1, 43.9, 34.6, 27.2, 23.9, 14.2, 13.4, 12.6, 8.6$; mass (ES⁺) m/z 329.4 [(M+1)⁺]; Anal. Calcd for C₁₈H₂₈N₆: C, 65.82; H, 8.59; N, 25.59. Found: C, 65.95; H, 8.43; N, 25.62.

***N,N*,9-Triethyl-6,7-dimethyl-6-phenyl-5,6-dihydroimidazo[5,1-*h*]pteridin-4-amine (13d):**

Yield: 48%; yellow oil; $R_f = 0.43$ (1:19, MeOH/CHCl₃); IR (KBr) ν_{\max} 3019, 2973, 2930, 2850, 1579 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) $\delta = 8.22$ (s, 1 H, ArH), 7.26 (s, 5 H, ArH), 4.26 (brs, 1 H, NH), 3.40-3.16 (m, 6 H, 3 x CH₂), 2.06 (s, 3 H, CH₃), 1.91 (s, 3 H, CH₃), 1.36 (t, $J = 7.5$ Hz, 3 H, CH₃), 1.11 (t, $J = 7.1$ Hz, 6 H, 2 x CH₃); ¹³C NMR (50 MHz, CDCl₃) $\delta = 156.1, 148.5, 147.4, 144.9, 143.1, 131.0, 128.7, 127.9, 126.5, 126.0, 120.2, 57.6, 44.2, 28.9, 23.8, 13.9, 13.4, 12.5$; mass (ES⁺) m/z 377.3 [(M+1)⁺]; Anal. Calcd for C₂₂H₂₈N₆: C, 70.18; H, 7.50; N, 22.32. Found: C, 70.14; H, 7.38; N, 22.48.

Acknowledgments

Central Drug Research Institute communication number is 7754. S. S. is thankful to CSIR, New Delhi for providing fellowship. The authors acknowledge the suggestion made by one of referees regarding the effect of *N*-atom in hetero arene ring on π cyclization.

Supporting Information Available: ¹H and ¹³C NMR spectra of the compounds (7a-m, 8a-h, 12a-r, and 13a-d).

REFERENCES

- (1) For review on privileged structures as starting point for library synthesis see: Horton, D. A.; Bourne, G. T.; Smythe, M. L. *Chem. Rev.* **2003**, *103*, 893-930.
- (2) (a) Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S. *J. Med. Chem.* **1988**, *31*, 2235-2246. (b) Smith, R. G.; Van der Ploeg, L. H. T.; Howard, A. D.; Feighner, S. D.; Cheng, K.; Hickey, G. J.; Wyvratt Jr., M. J.; Fisher, M. H.; Nargund, R. P.; Patchett, A. A. *Endocr. Rev.* **1997**, *18*, 621-645. (c) Mason, J. S.; Morize, I.; Menard, P. R.; Cheney, D. L.; Hulme, C.; Labaudiniere, R. F. *J. Med. Chem.* **1999**, *42*, 3251-3264. (d) Patchett, A. A.; Nargund, R. P. *Ann. Rep. Med. Chem.* **2000**, *35*, 289-298. (e) Nicolaou, K. C.; Pfefferkorn, J. A.; Roecker, A. J.; Cao, G.-Q.; Barluenga, S.;

Mitchell, H. J. *J. Am. Chem. Soc.* **2000**, *122*, 9939-9953. (f) Horton, D. A.; Bourne, G. T.; Smythe, M. L. *J. Comput. Aided. Mol. Des.* **2002**, *16*, 415-430. (g) Horton, D. A.; Bourne, G. T.; Smythe, M. L. *Mol. Divers.* **2002**, *5*, 289-304. (h) Guo, T.; Hobbs, D. W. *Assay Drug Dev. Technol.* **2003**, *1*, 579-592. (i) Müller, G. *Drug Discov. Today* **2003**, *8*, 681-691. (j) DeSimone, R. W.; Currie, K. S.; Mitchell, S. A.; Darrow, J. W.; Pippin, D. A. *Comb. Chem. High Throughput Screen.* **2004**, *7*, 473-493. (k) Bondensgaard, K.; Ankersen M.; Thogersen, H.; Hansen, B. S.; Wulff, B. S.; Bywater, R. P. *J. Med. Chem.* **2004**, *47*, 888-899. (l) Mills, J. S.; Showell, G. A. *Expert Opin. Investig. Drugs*, **2004**, *13*, 1149-1157.

- (3) For recent review see: Prien, O. *ChemBioChem* **2005**, *6*, 500-505.
- (4) (a) Fernández, D.; Ahaidar, A.; Danelón, G.; Cironi, P.; Marfil, M.; Pérez, O.; Cuevas, C.; Albericio, F.; Joule, J. A.; Álvarez, M. *Monatsh. Chem.* **2004**, *135*, 615-627. (b) Bräse, S.; Gil, C.; Knepper, K. *Bioorg. Med. Chem.* **2002**, *10*, 2415-2434. (c) Balaban, A. T.; Oniciu, D. C.; Katritzky, A. R. *Chem. Rev.* **2004**, *104*, 2777-2812. (d) Chen, J.-J.; Fang, H.-Y.; Duh, C.-Y.; Chen, I.-S. *Planta Med.* **2005**, *71*, 470-475. (e) Nicolaou, K. C.; Baran, P. S.; Zhong, Y.-L.; Sugita, K. *J. Am. Chem. Soc.* **2002**, *124*, 2212-2220.
- (5) (a) Kundu, B.; Sawant, D.; Chhabra, R. *J. Comb. Chem.* **2005**, *7*, 317-321. (b) Kundu, B.; Sawant, D.; Partani, P.; Kesarwani, A. P. *J. Org. Chem.* **2005**, *70*, 4889-4892. (c) Duggineni, S.; Sawant, D.; Saha, B.; Kundu, B. *Tetrahedron* **2006**, *62*, 3228-3241. (d) Sharma, S.; Saha, B.; Sawant, D.; Kundu, B. *J. Comb. Chem.* **2007**, *9*, 783-792. (e) Saha, B.; Sharma, S.; Sawant, D.; Kundu, B. *Tetrahedron* **2008**, *64*, 8676-8684. (f) Agarwal, P. K.; Sawant, D.; Sharma, S.; Kundu, B. *Eur. J. Org. Chem.* **2009**, 292-303. (g) Agarwal, P. K.; Sharma, S. K.; Sawant, D.; Kundu, B. *Tetrahedron* **2009**, *65*, 1153-1161.
- (6) Contour-Galcéra, M.-O.; Poitout, L.; Moinet, C.; Morgan, B.; Gordon, T.; Roubert, P.; Thurieau, C. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 741-745.
- (7) (a) Dubuisson, M. L.; De Wergifosse, B.; Trouet, A.; Baguet, F.; Marchand-Brynaert, J.; Rees J.-F. *Biochem. Pharmacol.* **2000**, *60*, 471-478. (b) Cavalier, J.-F.; Burton, M.; Dussart, F.; Marchand, C.; Rees, J.-F.; Marchand-Brynaert, J. *Bioorg. Med. Chem.* **2001**, *9*, 1037-1044.
- (8) Mulvihill, M. J.; Ji, Q.-S.; Werner, D.; Beck, P.; Cesario, C.; Cooke, A.; Cox, M.; Crew, A.; Dong, H.; Feng, L.; Foreman, K. W.; Mak, G.; Nigro, A.; O'Connor, M.; Saroglou, L.; Stolz, K. M.; Sujka, I.; Volk, B.; Weng, Q.; Wilkes, R. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 1091-1097.
- (9) Zimmermann, P. J.; Brehm, C.; Buhr, W.; Palmer, A. M.; Volz, J.; Smon, W.-A. *Bioorg. Med. Chem.* **2008**, *16*, 536-541.
- (10) Dwyer, M. P.; Paruch, K.; Alvarez, C.; Doll, R. J.; Keertikar, K.; Duca, J.; Fischmann, T. O.; Hruza, A.; Madison, V.; Lees, E.; Parry, D.; Seghezzi, W.; Sgambellone, N.; Shanahan, F.; Wiswell, D.; Guzi, T. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 6216-6219.
- (11) Brown, A.; Henderson, A.; Lane, C.; Lansdell, M.; Maw, G.; Monaghan, S. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 4697-4699.
- (12) Thomson, C. M.; Herring, P. J.; Campbell, A. K. *J. Biolumin. Chemilumin.* **1997**, *12*, 87-91.
- (13) (a) Adamczyk, M.; Akireddy, S. R.; Johnson, D. D.; Mattingly, P. G.; Pan, Y.; Reddy, R. E. *Tetrahedron* **2003**, *59*, 8129-8142. (b) Abushanab, E.; Bindra, A. P.; Goodman, L. *J. Heterocycl. Chem.* **1975**, *12*, 207-209. (c) Abushanab, E.; Bindra, A. P.; Goodman, L. *J. Org. Chem.* **1975**, *40*, 3379-3381. (d) Basiuk, V. A. *Russ. Chem. Rev.* **1997**, *66*, 187-204. (e) Porter,

- A. E. A. In *Pyrazines and their Benzo Derivatives in Comprehensive Heterocyclic Chemistry*; Katritzky, A. R.; Rees, C. W., Eds.; Pergamon Press: Oxford, New York, 1984; Vol. 3, pp. 157–197. (f) Devillers, I.; Arrault, A.; Olive, G.; Marchand-Brynaert, J. *Tetrahedron Lett.* **2002**, *43*, 3161–3164.
- (14) (a) Ilyin, A. P.; Kobak, V. V.; Dmitrieva, I. G.; Peregudova, Y. N.; Kustova, V. A.; Mishunina Y. S.; Tkachenko, S. E.; Ivachtchenko, A. V. *Eur. J. Org. Chem.* **2005**, 4670–4679. (b) Gopalsamy, A.; Shi, M. *Org. Lett.* **2003**, *5*, 3907–3909.
- (15) (a) Trček, T.; Verček, B. *Synthesis* **2006**, 3437–3442. (b) Trček, T.; Meden, A.; Verček, B. *Synlett* **2000**, 1458–1460.
- (16) Parchinsky, V. Z.; Shuvalova, O.; Ushakova, O.; Kravchenko, D. V.; Krasavin, M. *Tetrahedron Lett.* **2006**, *47*, 947–951.
- (17) Chen, P.; Doweyko, A. M.; Norris, D.; Gu, H. H.; Spergel, S. H.; Das, J.; Moquin, R. V.; Lin, J.; Wityak, J.; Iwanowicz, E. J.; McIntyre, K. W.; Shuster, D. J.; Behnia, K.; Chong, S.; de Fex, H.; Pang, S.; Pitt, S.; Shen, D. R.; Thrall, S.; Stanley, P.; Kocy, O. R.; Witmer, M. R.; Kanner, S. B.; Schieven, G. L.; Barrish, J. C. *J. Med. Chem.* **2004**, *47*, 4517–4529.
- (18) (a) Laird, D. W.; Poole, R.; Wikström, M.; Altena, I. A. *J. Nat. Prod.* **2007**, *70*, 671–674. (b) Srikrishna, A.; Pardeshi, V. H.; Satyanarayana, G. *Tetrahedron Lett.* **2007**, *48*, 4087–4090.
- (19) (a) Shiho, D.-i.; Tagami, S.; *J. J. Am. Chem. Soc.* **1960**, *82*, 4044–4054. (b) Sarges, R.; Howard, H. R.; Browne, R. G.; Lebel, L. A.; Seymour, P. A.; Koe, B. K. *J. Med. Chem.* **1990**, *33*, 2244–2254. (c) Ohmori, J.; Shimizu-Sasamata, M.; Okada, M.; Sakamoto, S. *J. Med. Chem.* **1997**, *40*, 2053–2063 (d) Unciti-Broceta, A.; Pineda-de-las-Infantas, M. J.; Díaz-Mochón, J. J.; Romagnoli, R.; Baraldi, P. G.; Gallo, M. A.; Espinosa, A. *J. Org. Chem.* **2005**, *70*, 2878–2880. (e) Moarbess, G.; Deleuze-Masquefa, C.; Bonnard, V.; Gayraud-Paniagua, S.; Vidal, J.-R.; Bressolle, F.; Pinguet, F.; Bonnet, P.-A. *Bioorg. Med. Chem.* **2008**, *16*, 6601–6610. (f) Ceccarelli, S.; D'Alessandro, A.; Prinzivalli, M.; Zanarella, S. *Eur. J. Med. Chem.* **1998**, *33*, 943–955. (g) Shrestha, K. S.; Honda, K.; Asami, M.; Inoue, S. *Bull. Chem. Soc. Jpn.* **1999**, *72*, 73–83. (h) Gleave, D. M.; Brickner, S. J.; Manninen, P. R.; Allwine, D. A.; Lovasz, K. D.; Rohrer, D. C.; Tucker, J. A.; Zurenko, G. E.; Ford, C. W. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 1231–1236.
- (20) Cox, E. D.; Cook, J. M. *Chem. Rev.* **1995**, *95*, 1797–1842.
- (21) The commercial availability of the isomers of amino pyridine and amino pyrimidine (2-amino-3-chloropyridine, 4-amino-3-chloropyridine and 4-amino-5-chloropyrimidine) are limited.